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ABSTRACT  
   
Objective: The purpose of this randomized parallel arm trial was to 
demonstrate the effects of daily fish oil supplementation (600mg per day for 
eight weeks) on body composition and body mass in young healthy women, 
aged 18-38, at a large southwestern university.  
Design: 26 non-obese (mean BMI 23.7±0.6 kg/m2), healthy women (18-
38y; mean, 23.5±1.1 y) from a southwestern Arizona university campus 
community completed the study. Subjects were healthy, non-smokers, 
consuming less than 3.5 oz of fish per week according to self-report. Participants 
were randomized to one of two groups: FISH (600 mg omega-3 fatty acids 
provided in one gel capsule per day), or CON (1000 mg coconut oil placebo 
provided in one gel capsule per day). Body weight, BMI, and percent body fat 
were measured using a stadiometer and bioelectrical impedance scale at the 
screening visit and intervention weeks 1, 4, and 8. 24-hour dietary recalls were 
also performed at weeks 1 and 8.  
Results: 8 weeks of omega-3 fatty acid supplementation did not 
significantly alter body weight (p=0.830), BMI (p=1.00), or body fat percentage 
(p=0.600) as compared to placebo. Although not statistically significant, 24-hour 
dietary recalls performed at the beginning and end of the intervention revealed a 
trend towards increased caloric intake in the FISH group and decreased caloric 
intake in the CON group throughout the course of the study (p=0.069). If 
maintained, this difference in caloric intake could have physiological relevance.  
 Conclusions: Omega-3 fatty acids do not significantly alter body weight or 
body composition in healthy young females. These findings do not refute the 
  ii 
current recommendations for Americans to consume at least 8 oz of omega-3-
rich seafood per week, supplying 250 mg EPA and DHA per day. More research is 
needed to investigate the potential for omega-3 fatty acids to modulate daily 
caloric intake.  
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Chapter 1 
INTRODUCTION 
American adults use omega-3 fatty acid supplements more than any 
other non-vitamin, non-mineral natural product available. In a 2007 survey, 37% 
of adults who had used natural products within the previous thirty days had used 
an omega-3 supplement (National Center for Complementary and Alternative 
Medicine, 2009). Omega-3 fatty acids are widely acclaimed for their anti-
inflammatory properties (Calder, 2006), and health organizations such as the 
American Heart Association and US Food and Drug Administration have 
recommended Americans include omega-3-rich foods such as fish as part of a 
well-balanced diet (Flock & Kris-Etherton, 2011; Kris-Etherton, Harris, & Appel, 
2002). Yet as obesity levels rise in the United States (Carroll & Surveys, 2010), 
the effects of increased omega-3 fatty acids on body composition in healthy 
people are unknown. 
 The ability of omega-3 fatty acids to inhibit the production of 
proinflammatory prostaglandins has been demonstrated to attenuate the severity 
of chronic inflammatory diseases such as coronary artery disease (Kris-Etherton 
et al., 2002) and rheumatoid arthritis (Calder, 2006). The omega-3 fats found in 
fish oil are also believed to have beneficial effects in autoimmune disorders, 
asthma, inflammatory bowel diseases (Calder, 2006), and some forms of cancer 
(Calder, 2006; Connor, 2000; Teitelbaum & Allan Walker, 2001), all of which are 
related to chronic inflammatory states (Calder, 2006).  
Despite the fact that obesity is a chronic inflammatory condition plaguing 
over 60% of American adults (Wyatt, Winters, & Dubbert, 2006), studies aiming 
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to demonstrate a link between fish oil intake and adiposity are inconclusive. 
Interestingly, omega-3 fatty acids have been used to increase body mass in 
patients with cancer cachexia (Colomer et al., 2007; Giacosa & Rondanelli, 2008; 
Grimble, 2003). Furthermore, one recent study demonstrated a down-regulation 
of thermogenic activity in brown adipose tissue in mice after inhibition of 
inflammatory prostaglandin production, suggesting omega-3 fatty acids may 
increase body mass and reduce basal metabolic rate (Vegiopoulos et al., 2010). 
Alternatively, a correlational study observed an inverse relationship between 
plasma omega-3 levels and body weight (Micallef, Munro, Phang, & Garg, 2009), 
and some studies have demonstrated enhanced fat loss by incorporating omega-
3 supplementation into a weight loss intervention (Hill, Buckley, Murphy, & 
Howe, 2007; Kabir et al., 2007; Noreen et al., 2010). However, others have 
found no significant changes in body mass after fish oil supplementation (Defina, 
Marcoux, Devers, Cleaver, & Willis, 2011; Fontani et al., 2005; Moore et al., 
2006; Noreen et al., 2010), or have had difficulty demonstrating these effects in 
women (Thorsdottir et al., 2007). 
In addition to these mixed results, the sample selections for most human 
interventions have made it difficult to generalize results to relatively healthy 
populations. Most clinical trials have employed subjects who are already obese or 
chronically inflamed (Hill et al., 2007; Kabir et al., 2007; Kunesová et al., 2006; 
Moore et al., 2006; Thorsdottir et al., 2007; Warner, Ullrich, Albrink, & Yeater, 
1989), and some have paired omega-3 fatty acid supplementation with a weight 
loss intervention rather than observing its effects independently (Hill et al., 2007; 
Kunesová et al., 2006; Moore et al., 2006; Thorsdottir et al., 2007; Warner et al., 
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1989). Moreover, only a few human interventions have tested these effects in 
young adults (Couet, Delarue, Ritz, Antoine, & Lamisse, 1997; Noreen et al., 
2010). One of these studies, conducted by Couet, et al., demonstrated an 
increase in fat oxidation and decrease in body fat over the course of three weeks 
when visible dietary fat was substituted with 6 grams of fish oil per day. 
However, the sample size was relatively small (seven total subjects), and only 
one female subject was used (Couet et al., 1997).  
Whether omega-3 fatty acids modulate body composition in healthy 
young women has yet to be investigated, despite the current recommendations 
for Americans to regularly consume sources of omega-3 fatty acids. More 
research is needed to determine if there are any unintended consequences of the 
current fish intake recommendations for young, healthy adult women, and how 
increased omega-3 intake may alter the susceptibility of this population to 
becoming overweight.  
Purpose of Study 
The primary objective of this randomized parallel arm trial was to 
demonstrate the effects of daily fish oil supplementation (600mg per day for 
eight weeks) on body composition and body mass in young healthy women, 
aged 18-40, at a large southwestern university.  
Research Aim & Hypothesis 
It was hypothesized that fish oil supplementation (600 mg per day) would 
have no effect on body weight or body composition by the end of the eight week 
period.  
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Definition of Terms 
• BMI: [weight (in pounds)/height (in inches)2] x 703; underweight is 
<18.5 kg/m2, normal is 18.5-24.9 kg/m2, overweight is 25.0-29.9 
kg/m2, obese is >30 kg/m2(American Dietetic Association, 2011) 
• Omega-3 fatty acids: polyunsaturated fatty acids, including alpha-
linolenic acid (ALA; 18:3 n-3), docosahexaenoic acid (DHA; 22:6 n-3), 
and eicosapentaenoic acid (EPA; 20:5 n-3) (Connor, 2000) 
• Prostaglandins: lipid mediator involved in the inflammation and 
immune response (Tilley, Coffman, & Koller, 2001) 
• Regular smoker: use of 10 or more cigarettes per day (Moran, 2004) 
• Training athlete: participating in purposeful, moderate to vigorous 
exercise more than 5 times per week 
Delimitations 
Subjects were women aged 18-38 years with no unresolved health issues. 
The participants attended a large university in the southwestern U.S.  
Exclusion criteria included regular smoking, BMI of less than 18.5 or more than 
30 kg/m2, and regular intake of omega-3 supplements and/or prescription 
medications that may interfere with body weight or inflammatory state (such as 
corticosteroids or non-steroidal anti-inflammatory drugs). Any subjects 
consuming more than 1 serving of fish or other omega-3-rich food per week, 
vegetarians, and subjects trying to lose or gain weight were also excluded. 
Furthermore, competing and/or training athletes and women who were pregnant 
or lactating were not included.  
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Limitations 
• Dietary omega-3 intake could alter inflammatory prostaglandin 
production in both the fish oil and control group. This limitation was 
minimized using a validated food frequency questionnaire to exclude 
study participants who regularly meet or exceed the American Heart 
Association’s fish intake recommendations (3.5oz of fish twice per 
week).  
• Natural fluctuations in body weight may occur due to hormonal cycles 
in women. To reduce this limitation, measurements were taken at a 
similar point in each woman’s cycle (every 4 weeks).  
• External factors such as lack of sleep or psychological stress may 
impact inflammatory state and body weight.  
• The short time period of the study may not have reflected significant 
changes in body weight or body composition. It is possible that a 
longer study period would be necessary to obtain valid and reliable 
results.  
• The subject pool was relatively small (n=26). A larger study using 








 Obesity Prevalence. Over two-thirds of all American adults are either 
overweight or obese according to results from the 2007-2008 National Health 
and Nutrition Examination Survey (NHANES) (Carroll & Surveys, 2010), making a 
reduction in obesity prevalence one of the top national health objectives for 2010 
(Pisarik, 2005). Body mass index (BMI, equal to weight in kilograms divided by 
height in meters squared), is most frequently used to classify obesity (BMI ! 30 
kg/m2) and overweight (BMI 25-29.9 kg/m2) (Carroll & Surveys, 2010). 
Overweight and obesity are the result of a positive energy balance. These 
conditions are characterized by an increase in body weight, particularly in 
adiposity, and are positively correlated with morbidity, mortality, and decreased 
longevity (Pisarik, 2005). More specifically, obesity has been linked to increased 
risk of a myriad of chronic diseases, including type 2 diabetes, coronary heart 
disease, and some forms of cancer (Pisarik, 2005; Wellen & Hotamisligil, 2003). 
It is estimated that the United States spends nearly $93 billion annually due to 
obesity and its comorbidities, which is nearly 10% of the nation’s yearly health 
costs (Pisarik, 2005). The negative medical consequences linked to obesity could 
arise from the chronic, low-grade inflammatory state that seems to originate 
primarily in white adipose tissue under obesogenic conditions, ultimately leading 
to metabolic disruptions (Todoric et al., 2006; Wellen & Hotamisligil, 2003).  
White Adipose Tissue. One of the chief metabolic roles of white adipose 
tissue (WAT) is energy storage (Trayhurn & Beatie, 2001). Lipolysis (the 
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breakdown of stored fats) or lipogenesis (the synthesis of triacylglycerols for 
storage) occur depending on the body’s energy balance and corresponding 
hormonal and neural signals. For instance, during periods of negative energy 
balance and low blood glucose, a decrease in insulin and increase in glucagon 
and epinephrine stimulates the release of free fatty acids (FFAs) from WAT 
(Ahima & Flier, 2000; Gropper, Smith, & Groff, 2009). Once in circulation, FFAs 
may then be oxidized to generate usable energy in the form of adenosine 
triphosphate (ATP) (Ahima & Flier, 2000). 
WAT is primarily composed of lipid-containing cells called adipocytes, but 
also contains collagen, blood vessels, and immune cells, and functions as an 
important endocrine organ (Ahima & Flier, 2000). Even under healthy conditions, 
WAT produces potent hormones and proinflammatory molecules, termed 
adipokines, that play important roles in energy homeostasis (Wellen & 
Hotamisligil, 2003). Adiponectin and leptin are examples of adipokines released 
by WAT.  
The synthesis and release of the adipokine leptin is positively correlated 
with adiposity (Drevon, 2005). When blood glucose is elevated or when 
adipocytes are full, leptin is secreted from WAT. Leptin works to restore energy 
homeostasis by decreasing appetite and stimulating cellular glucose uptake by 
increasing insulin sensitivity (Gropper et al., 2009). Leptin takes action in the 
arcuate nucleus of the hypothalamus by stimulating anorexigenic hormones such 
as melanocyte stimulating hormone (MSH) (Gropper et al., 2009; Ronti, 
Lupattelli, & Mannarino, 2006). It also increases lipid oxidation in myocytes by 
inhibiting malonyl CoA, which is one of the first intermediates produced in fatty 
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acid synthesis. During periods of high glucose levels, malonyl CoA is elevated 
and inhibits lipid oxidation. By blocking malonyl CoA, leptin is able to increase 
rates of lipid oxidation and thus decrease lipid storage. As adipocyte size 
decreases, leptin production also decreases, and appetite inhibition is reduced 
(Gropper et al., 2009; Ronti et al., 2006).  
Adiponectin is also expressed in WAT, and appears to be protective 
against coronary heart disease and insulin resistance. Evidence suggests that 
adiponectin is able to increase insulin sensitivity by promoting lipid oxidation, 
which leads to reduced triglyceride content in hepatocytes and myocytes (Díez & 
Iglesias, 2003). Research has demonstrated a synergistic effect of adiponectin 
and leptin, as the two hormones seem to work together in order to increase 
insulin sensitivity (Ronti et al., 2006). Interestingly, adiponectin levels are lower 
in obese as compared to healthy populations, and levels seem to increase with 
weight loss. Moreover, the action of adiponectin is inhibited by inflammatory 
markers interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- !), which are 
characteristic of obesity-related inflammation (Ronti et al., 2006).  
Brown Adipose Tissue. The presence of brown adipose tissue (BAT) is 
well known in human infants and small mammals. Its function is extremely 
different from that of WAT, as it is used by newborns and small mammals to 
generate heat and normalize core body temperature (Calder, 2006; Surette, 
2008). Studies observing cell differentiation in rodents have demonstrated a 
close relationship between BAT and muscle cells. These studies have observed 
that BAT expresses genes generally thought to be uniquely characteristic to 
myocytes, whereas WAT does not express these genes (Cypess et al., 2009). 
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Moreover, a 2008 study demonstrated that myogenic precursors in rodents 
expressing a particular myogenic transcription factor either developed into 
muscle cells or BAT, but not WAT (Seale et al., 2008).  
BAT is a strong contributor to basal energy expenditure due to its high 
expression of uncoupling protein 1 (UCP1)—a potent thermogenic mediator 
(Petrovic et al., 2010). As a proton transporter, UCP1 uncouples oxidative 
phosphorylation from ATP synthesis at the inner mitochondrial membrane. It is 
able to do so by allowing hydrogen ions that had been pumped out of the 
mitochondrial membrane by the electron transport chain to return to the 
mitochondria rather than going through ATP synthase. This decreases the 
concentration of hydrogen ions in the inner membrane space. Without this 
proton gradient, the efficiency of ATP synthesis is reduced and energy is 
transferred from food directly into heat rather than useable ATP (Celi, 2009; 
Gropper et al., 2009; Klingenberg, 2001; Seale et al., 2008). Food intake and 
exposure to cold temperatures are external stimuli that may stimulate BAT 
thermogenesis. BAT is tightly innervated by the sympathetic nervous system, 
allowing it to respond to environmental changes such as low temperatures 
(Zingaretti et al., 2009).  
Previously, it was believed that the presence of BAT in adult humans was 
rare and metabolically insignificant (Celi, 2009). However, recent research has 
demonstrated otherwise (Cypess et al., 2009; Seale et al., 2008). Studies have 
shown the presence of brown fat in the muscles of the subclavicular region, 
neck, chest, and abdomen of adult humans using computerized tomography and 
the introduction of a radioactive form of glucose (FDG) into tissues. These 
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techniques enable researchers to characterize the metabolic activity of the 
tissues (Cypess et al., 2009). Virtanen, et al. used these techniques to identify 
BAT in healthy volunteers on two occasions: once in room temperature, and the 
other in a chilled environment. All subjects demonstrated increased FDG uptake 
in subclavicular adipose. Tissue biopsy confirmed the presence of BAT in varying 
amounts in each subject. One subject was found to have 63g of BAT, which the 
authors predict would burn the caloric equivalent of over 8 pounds of white 
adipose tissue in just one year (Virtanen et al., 2009).  
Not only have studies established the presence of BAT in adults, but they 
have also demonstrated correlations between quantities of BAT and gender, age, 
and body fatness. Using FDG and positron emission tomography-computed 
tomography (PET-CT), Cypess, et al. demonstrated that the prevalence of BAT in 
women (BAT activity was detected in 7.5% of women in the study) was more 
than in men (3.1% of males in the study showed BAT activity), concluding that 
women were three times more likely to have substantial BAT than men. 
Furthermore, the authors noted that subjects under 50 years of age had the 
most detectable BAT (p<0.001), and that the amount of BAT was inversely 
correlated with obesity. It is believed that even more BAT would have been 
detected had participants been subjected to a BAT stimulus, such as a cold 
atmosphere (Cypess & Kahn, 2010; Farmer, 2009). Similar results were seen in a 
study by Zingaretti, et al., in which investigators analyzed adipose tissue samples 
from the necks of 35 patients. Zingaretti and colleagues found that 1/3 of the 
samples had regions expressing high levels of UCP1. These regions, termed “BAT 
islands,” were also much more densely innervated than WAT regions. The 
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highest levels of BAT were detected in the youngest and the leanest of the 35 
subjects; the mean BMI for subjects with UCP1 expression was 23± 1 kg/m2, 
whereas those with no UCP1 expression had a mean BMI of 26± 1 kg/m2 
(p<0.03). However, the study design did not allow the authors to separate 
leanness and age in order to deduce if it was just one of these variables or a 
combination of both that influenced UCP1 expression (Zingaretti et al., 2009).   
 
Omega-3 and Polyunsaturated Fatty Acid Overview  
Dietary Sources and Metabolism. Polyunsaturated fatty acids (PUFAs) are 
a broad classification of fatty acids that contain two or more carbon-carbon 
double bonds. They can be further classified into omega-3 (n-3 FAs) or omega-6 
fatty acids (n-6 FAs) depending on the location of their first double bond 
(Teitelbaum & Allan Walker, 2001). Although both are imperative in normal 
metabolism, n-3 and n-6 FAs must be obtained from dietary sources since 
humans lack the enzymes necessary for their de novo synthesis (El-Badry, Graf, 
& Clavien, 2007). Thus, n-3 and n-6 FAs are considered essential fatty acids 
(EFAs). EFAs have numerous biochemical roles, including energy storage, cell 
signaling, cell membrane structure, and inflammatory mediation (El-Badry et al., 
2007; Surette, 2008).   
Omega-3 fatty acids occur in foods in various structures depending on 
their original source. All n-3 FAs contain between 18 and 22 carbon atoms with 
their first double bond located at the third carbon from the methyl end of the 
carbon chain (Calder, 2006). However, eicosapentaenoic acid (EPA, 20:5 n-3) 
and docosahexaenoic acid (DHA, 22:6 n-3) are the most biologically available 
  12 
sources of dietary n-3 FAs, and are abundant in some animal foods. EPA and 
DHA are long chain n-3 FAs in comparison to alpha linolenic acid (ALA, 18:3 n-3), 
the common short chain n-3 FA. High fat fish such as salmon and tuna are 
particularly rich in EPA and DHA (Molendi-Coste, Legry, & Leclercq, 2011), but 
limited amounts of n-3 FAs are also found in some cuts of beef, poultry, and 
eggs depending on the feeding patterns of the animal. ALA is found in plant oils, 
including walnut and flaxseed oils (Table 1) (A. P. Simopoulos, 2001a). Despite 
large disparities in n-3 FA content between fish species, marine foods generally 
have between 5 and 15 times the amount of n-3 FAs as poultry or other animal 
meats (Howe, Meyer, Record, & Baghurst, 2006). Enriched foods have also been 
developed to enhance levels of EPA and DHA in foods, or to add them to non-
animal foods (Mantzioris et al., 2000).  
Table 1. Dietary Sources of PUFAs1 
Marine Sources 
Food Source EPA + DHA (g/4oz) 2 Omega-6 FA (g/4 oz) 2 
Salmon, wild, Atlantic, 
Chinook, or Coho 
1.2-2.4 0.3-0.5 
Anchovies, Herring, or Shad 1.6-2.7 0.1-0.3 
Tuna, Bluefin, fresh 1.3-1.7 0.1 
Tuna, Albacore, canned in 
water 
1.0 0.1 
Swordfish 0.9 0.05 
Salmon, Pink, farmed 0.4 0.1 
Crab, Blue or Snow 0.4-0.5 0.08 
Tuna, light, canned in water 0.3 0.1 
Cod, Alaskan 0.2 0.03 
Shrimp 0.07 0.02 
Eggs, Meat, and Poultry 
Food Source EPA + DHA (g/4oz) 2 Omega-6 FA (g/4 oz) 2 
Egg, fresh 0.033 0.83 
Chicken, broilers or fryers, no 
skin or bone 
0.006 0.4 
Beef, flank steak 0.003 0.3 
Beef, grass fed, strip steaks, 0.002 0.1 
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lean only 
Beef, ground, 70% lean 
meat, 30% fat 
0.000 0.7 
Plant oils 
Food Source ALA (g/Tbsp) 4 LA (g/Tbsp) 4 
Flaxseed oil, cold pressed 7.3 0.004 
Canola oil 1.3 2.7 
Walnut oil 1.4 7.2 
Soybean oil 0.9 6.9 
Corn oil 0.2 7.3 
Olive oil 0.1 1.3 
Safflower oil 0.0 10.1 
Sunflower oil 0.0 3.9 
Coconut oil 0.0 0.2 
1Source: U.S. Department of Agriculture, Agricultural Research Service, Nutrient 
Data Laboratory, 2012, USDA National Nutrient Database for Standard Reference, 
Release 24, Available at: http://ndb.nal.usda.gov/. 
2Values based on 4oz raw 
3Based on 1 large egg (50g) 
41 Tbsp oil = 13.6 g 
 
Marine sources of n-3 FAs are distinct from plant sources, such as nuts, 
seeds, and soy, which supply alpha linolenic acid (ALA, 18:3 n-3) (A. P. 
Simopoulos, 2001a). ALA is believed to be one of the least usable forms of n-3 
FAs since it must be converted to the longer chain n-3 FAs (EPA and DHA) in the 
endoplasmic reticulum of hepatocytes before it can be used. The rate at which 
ALA is converted to longer chain n-3 FAs is dependent on the ratio of n-6 to n-3 
FAs available in the diet (Arterburn, Hall, & Oken, 2006). Delta-6 desaturase is 
the rate-limiting enzyme in the conversion of ALA to EPA, and adds a double 
bond to the original ALA structure. Elongases then add carbon units to the 
molecule, and delta-5 desaturase finally adds another double bond to form EPA. 
DHA is synthesized next via delta-6 desaturase and beta-oxidation (G. C. Burdge 
& Calder, 2005).  
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The conversion of ALA to EPA and DHA is relatively inefficient in humans 
(G. C. Burdge & Calder, 2005), but evidence has shown that women are more 
efficient in this conversion than men. Conversion rates of ALA to EPA and DHA 
have been shown to be up to 21% and 9%, respectively, in females, as 
compared to less than 8% and less than 4% in males (Arterburn et al., 2006). It 
is possible that the increased efficiency of this process in females may be related 
to the high demands for DHA during pregnancy (G. C. Burdge & Calder, 2005). 
The conversion rate of ALA to EPA may be further altered by dietary n-6 FA 
levels, since metabolism of linoleic acid (an n-6 FA) competes with ALA for the 
rate-limiting enzyme delta-6 desaturase.  
Linoleic acid (LA) represents the n-6 FAs and is found in high levels in 
vegetable oils such as safflower, sunflower, and corn oil (A. P. Simopoulos, 
2001b). Once in the body, LA is efficiently converted to arachidonic acid (AA). LA 
contains an 18-carbon chain, while AA contains a 20-carbon chain. Both have cis 
double bonds beginning at the sixth carbon from the methyl end of the carbon 
chain (El-Badry et al., 2007). In order to convert LA to AA, LA is first converted 
to gamma-linoleic acid (18:3 n-6) by delta-6 desaturase. Elongases then add 
carbon units to form dihomo-gamma-linoleic acid (20:3 n-6). Delta-5 desaturase 
completes the process by adding another double bond to form AA (Wall, Ross, 
Fitzgerald, & Stanton, 2010). Like EPA, AA is a critical component of cellular 
plasma membranes, and plays a major role in cell signaling and inflammatory 
processes (El-Badry et al., 2007).  
Both ALA and LA metabolism utilize the same desaturases and elongases, 
but the resulting metabolites are very different (Calder, 2006). Activity of these 
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enzymes is regulated by numerous factors, including feedback inhibition related 
to dietary intake (El-Badry et al., 2007). Igarashi and colleagues provided 
rodents with a diet very low in n-3 FA for 15 weeks and compared expression 
and activity of elongases and delta-5 and 6 desaturases. Rats fed inadequate n-3 
FA showed significantly increased expression of delta-5 and 6 desaturases and 
elongases 2 and 5 in hepatocytes (p<0.05), suggesting transcription of these 
enzymes may be upregulated during periods of low n-3 FA intake in order to 
convert ALA to EPA and DHA (Igarashi, Ma, Chang, Bell, & Rapoport, 2007).  
Desaturase activity appears to change in fasting and fed states, as insulin 
may stimulate delta-6 desaturase and glucagon may decrease both delta-5- and 
6 desaturase activity (El-Badry et al., 2007). Brenner and colleagues found that 
fasting decreased delta-6 desaturase activity, and glucose refeeding increased 
activity in rodents (Brenner, 1981). Similarly, investigators observed that diabetic 
rats had overall low delta-6 desaturase activity, but this activity was increased 
when insulin was administered (Brenner, 1981). This hormonal regulation 
appears to hold true in humans as well. Medeiros and colleagues observed delta-
5 and delta-6 desaturase activity with respect to insulin levels in obese women. A 
positive correlation was found between insulin levels and desaturase activity in 
women with hyperinsulinemia, but a negative correlation was found between 
desaturase activity and obesity (El-Badry et al., 2007; Madeiros, Liu, Park, 
Chang, & Smith, 1995). 
Interestingly, desaturase activity in males tends to be lower than that of 
females (Arterburn et al., 2006). A study by Burdge and Wootton showed that 
conversion of ALA to EPA was 2.5 times greater in young women (mean age of 
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28 years) than men of a similar age, and conversion of ALA to DHA was over 200 
times greater in young women as compared to men (G. C. Burdge & Calder, 
2005; G. C. Burdge & Wootton, 2002). Estrogen is believed to lead to increased 
lipid oxidation, which is needed in the last step of the conversion of ALA to DHA. 
Thus, higher estrogen levels in women as compared to men could allow for 
increased DHA formation. This theory was supported by a study comparing ALA 
to DHA conversion rates in women receiving oral contraceptives (a source of 
estrogen) to women not taking contraceptives. Those on contraceptives 
demonstrated 62% greater DHA synthesis compared to the control group, 
suggesting estrogen may play a role in increasing the ALA to DHA conversion 
pathway (G. Burdge, 2004).  
Current versus Historical Intakes. It is estimated that Americans currently 
consume an average of one 3.5 oz serving of seafood per week (National Center 
for Complementary and Alternative Medicine, 2009). The 2010 Dietary Guidelines 
for Americans recommend Americans increase seafood intake to approximately 8 
oz per week (supplying 250mg EPA and DHA per day), citing in particular its 
importance in cardiac health (Flock & Kris-Etherton, 2011). The American Heart 
Association confirms these recommendations, suggesting Americans consume at 
least two 3.5 oz servings of fish per week (Kris-Etherton et al., 2002). The 
current adequate intake (AI) for n-3 FAs for adults aged 19-30 years is 1.6 g/d 
for males and 1.1 g/d for females. Despite the need for ALA to be converted into 
EPA and DHA, this level does not distinguish between ALA, EPA, and DHA intakes 
(Trumbo, Schlicker, Yates, & Poos, 2002).  
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Anthropological and epidemiological studies have demonstrated 
disparities between the typical Western diet and the hunter-gatherer diets of our 
Paleolithic ancestors approximately 2.5 million-10,000 years ago (Kuipers et al., 
2010; A. Simopoulos, 2006). The modern Western diet is generally high in LA-
rich foods, including refined vegetable oils and grains, and relatively low in fiber 
and phytochemicals from unprocessed plant foods (Cordain et al., 2005). 
Conversely, the Paleolithic diet was high in ALA-rich, unprocessed plant foods 
such as nuts and seeds, and low in cereal grains and high-fat proteins (Kuipers 
et al., 2010).  
Kuipers, et al., modeled Paleolithic diets using a database of Eastern 
African foods and knowledge of typical hunter-gatherer food collection strategies. 
Investigators found that our Paleolithic ancestors consumed significantly more n-
3 FAs and less n-6 FAs than those consuming the modern Western diet (Kuipers 
et al., 2010). The estimated n-6 FA to n-3 FA ratio of the Paleolithic diet is 
believed to have been close to 1:1, whereas the ratio in the typical Western diet 
is approximately 16:1 (A. Simopoulos, 2006).  
Perhaps the most significant changes to the food supply have occurred 
within the last two centuries with changes in food technology and agricultural 
practices. For instance, livestock was primarily grass-fed prior to the 19th century. 
This practice changed when the development of technologies such as the steam 
engine and railroad allowed for increased grain harvest, which could then be 
used as animal feed (Cordain et al., 2005). Grain-based diets led to changes in 
the fatty acid composition of meats, as grain-fed animals supply higher levels of 
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saturated and n-6 FAs than free-ranging, grass-fed animals (A. Simopoulos, 
2006).  
Furthermore, oil-seed processing led to stark increases in consumption of 
n-6 FA-rich vegetable oils in the 20th century (Cordain et al., 2005). For instance, 
soybean oil constituted approximately 0.006% of total calories consumed by 
Americans in 1909. By 1999, soybean oil consumption was over 1,000 times 
greater, comprising 7.38% of energy consumption (Blasbalg, Hibbeln, Ramsden, 
Majchrzak, & Rawlings, 2011). This increase in processed food availability is 
believed to have displaced n-3 FAs in the modern diet, causing an overall 
increase in n-6 FA and decrease in n-3 FA consumption (Blasbalg et al., 2011; 
Cordain et al., 2005).   
Despite the discrepancies between Paleolithic and modern PUFA intake, 
the human genome has only changed minimally, possibly contributing to the rise 
in chronic inflammatory conditions (Kuipers et al., 2010). The effect of this 
overabundance of n-6 FAs on biochemical processes such as gene transcription 
and regulation are unclear. Furthermore, the surplus of n-6 FA allows for 
increased production of AA metabolites, such as interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-!). These potent inflammatory cytokines have been 
found to lead to a prothrombotic, proaggregatory state, likely contributing to the 
development of chronic inflammatory conditions such as cardiovascular disease 
and autoimmune disorders (A. Simopoulos, 2006).  
 Observed changes in dietary n-6 to n-3 FA ratios could also explain why 
recent research has shown the Mediterranean diet to be particularly effective in 
reducing inflammatory diseases such as asthma and cardiovascular disease (A. 
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Simopoulos, 2006; A. P. Simopoulos, 2001a). Both the Paleolithic and 
Mediterranean diets are relatively high in plant foods, nuts and seeds, and 
protein sources such as fish, thus supplying significantly higher levels of mono- 
and polyunsaturated fats than the typical Western diet (A. P. Simopoulos, 
2001b). A crossover-study by Ambring, et al., demonstrated a statistically 
significant decrease in serum n-6 to n-3 phospholipid ratio when subjects were 
on a Mediterranean diet when compared to a Swedish diet. The total number of 
leukocytes was decreased by 10% (p<0.05), and the total number of platelets 
was decreased by 15% (p<0.001) after 4 weeks on the Mediterranean diet, 
suggesting a decreased risk for coronary artery disease. Investigators also 
observed a significant inverse correlation between DHA consumption and 
lymphocyte count regardless of diet (Swedish or Mediterranean), suggesting a 
link between DHA and decreased risk of coronary heart disease (Ambring et al., 
2006).  
Interestingly, a study by Kang, et al., demonstrated the capability of 
rodent cardiomyocytes to express a gene allowing for the conversion of n-6 FAs 
to n-3 FAs in order to bring the ratio closer to 1 (Kang et al., 2001). Although 
humans lack the enzymes necessary to perform this conversion, it is interesting 
that when present, these enzymes return EFA levels to a ratio similar to that 
believed to be optimal based on evolutionary studies (Kang et al., 2001).  
 
Biological Functions of PUFAs 
 
PUFAs as Energy Sources. Dietary lipids are energy dense, supplying 9 
kilocalories per gram (Brown, Isaacs, & Wooldridge, 2007). All dietary lipids, 
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whether saturated or unsaturated, undergo mitochondrial beta-oxidation (lipid 
oxidation) to generate ATP. However, evidence suggests that unsaturated fatty 
acids are more readily oxidized than saturated fatty acids of equal chain length 
(DeLany, Windhauser, Champagne, & Bray, 2000; Piers, Walker, Stoney, Soares, 
& O’Dea, 2002). There is also a positive linear relationship between the number 
of double bonds and oxidation rate of fatty acids, suggesting that saturated fatty 
acids are more likely to be stored in adipose tissue than unsaturated fatty acids 
(DeLany et al., 2000).  
Before fatty acid oxidation begins, long chain fatty acids must first be 
attached to carnitine by carnitine palmitoyl transferases (CPT) so that they may 
be transported into the mitochondrial matrix (Buckley & Howe, 2009). Here, they 
are activated to form fatty acyl-CoA (Eaton et al., 1996). The process of beta-
oxidation occurs in the mitochondria, generating energy in the form of FADH2, 
NADH, and acetyl-CoA (Eaton et al., 1996; Gropper et al., 2009).  
Effects on Gene Expression. PUFAs, including n-3 and n-6 FAs, may act as 
ligands for nuclear factors, which directly interact with DNA to regulate gene 
transcription (Bordoni, Di Nunzio, Danesi, & Biagi, 2006; Ferré, 2004). For 
instance, PUFAs are able to modulate their own metabolism by acting as ligands 
for peroxisome proliferator-activated receptors (PPARs), a family of transcription 
factors involved in inflammation and energy homeostasis (Molendi-Coste et al., 
2011).  
PPARs occur in three known isoforms: PPAR!, PPAR "/#, and PPAR$, each 
of which is transcribed from different genes. PPAR! is prevalent in hepatic, renal, 
cardiac, and skeletal muscle tissue (Ferré, 2004), and regulates expression of 
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genes involved in fatty acid transport and oxidation, inflammation, and cell 
proliferation (Stienstra, Duval, Müller, & Kersten, 2007). Because PPAR! 
increases fatty acid oxidation, its activation may lead to decreased fat storage. 
PPAR "/# is a regulator of lipid metabolism, wound healing, and development, 
and is prevalent in numerous tissues throughout the body (Ferré, 2004). Finally, 
PPAR$ occurs in four known isoforms which are widely expressed in white and 
brown adipose tissue, and to a lesser amount in immune cells (Bordoni et al., 
2006). In addition to lipid metabolism, PPAR$ plays a role in inflammation, 
adipocyte differentiation, and cell cycle regulation (Bordoni et al., 2006).  
Studies demonstrating the ability of PPARs to reduce transcription of pro-
inflammatory genes in adipocytes and hepatocytes have called attention to their 
antiobesogenic potential (Ferré, 2004). Moreover, studies have demonstrated 
that PPARs may act to decrease hypertrophy of adipocytes (Bordoni et al., 2006), 
and influence the differentiation of preadipocytes in order to form fewer 
proinflammatory, macrophage-type cells (Stienstra et al., 2007). All unsaturated 
fatty acids, including EPA, DHA, AA, and LA, have been shown to activate PPAR!, 
leading to increased expression of genes encoding enzymes needed for lipid 
oxidation (Ross, Moses, & Fearon, 1999). This leads to a consequential decrease 
in lipid accumulation in tissues (Ferré, 2004). Activation of PPAR$ by AA, DHA, 
EPA, and other PUFAs may also decrease inflammatory cytokine production in 
vasculature (Stienstra et al., 2007), and increase adipocyte secretion of 
antiobesogenic hormones such as leptin and adiponectin (Ferré, 2004).  
Long chain PUFAs, including both the n-3 and n-6 FAs, may also control 
lipid homeostasis by regulating the activation of sterol regulatory element-
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binding proteins (SREBPs) (Deckelbaum, Worgall, & Seo, 2006). SREBPs are a 
family of transcription factors important to lipid synthesis. SREBPs must be 
activated posttranscriptionally, but PUFAs have been shown to inhibit their 
activation, leading to decreased lipid synthesis (Deckelbaum et al., 2006; Eberle, 
Hegarty, Bossard, Ferre, & Foufelle, 2004).  
Incorporation into Plasma Membranes. Lipids are also incorporated into 
cellular plasma membranes, particularly in erythrocytes, platelets, and 
neutrophils, allowing them to play important roles in cell signaling (A. P. 
Simopoulos, 1999). Plasma membrane composition is reflective of dietary lipid 
intake, as n-3 and n-6 FAs compete with each other for assimilation into the 
phospholipid bilayer (Wall et al., 2010). Studies have demonstrated changes in 
erythrocyte morphology and composition in rodents after providing diets rich in 
either n-6 FAs or n-3 FAs. Increased n-3 FA consumption leads to an increased 
n-3 to n-6 FA ratio in the plasma membrane, and a consequential increase in n-3 
metabolite production (Surette, 2008; Teitelbaum & Allan Walker, 2001).  
The presence of long-chain PUFAs (including n-3 and n-6 FAs) in cell 
membranes enhances membrane fluidity. Multiple double bonds found in PUFAs 
contribute to a more disorganized plasma membrane structure. Because DHA is 
longer and contains more double bonds than EPA and AA, it is believed to create 
an even more fluid and disorganized plasma membrane structure (Gorjão et al., 
2009). This allows for improved cell-signaling by making membrane-bound 
receptors, enzymes, and transporters more accessible to signaling molecules 
such as G-proteins, kinases, and ion channels (Ross et al., 1999).  
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The PUFA (including both n-3 and n-6 FAs) content of cell membranes 
may modulate sodium and calcium channel ion pump function by stimulating 
their activity (Ross et al., 1999). Membrane-associated ion transport, which 
drives cellular processes such as metabolism, is a major contributor of the basal 
metabolic rate of mammals. Animals with high basal metabolic rates have been 
shown to have higher levels of PUFAs in their cell membranes, suggesting PUFAs 
may act as stimulators of enzymes needed in active transport and cell-signaling, 
such as calcium ATPases and sodium-potassium ATPases (Hulbert, Turner, 
Storlien, & Else, 2005). Infante, et al., demonstrated that high levels of PUFA 
(particularly n-3 FA) in the membranes of muscle cells led to increased activity of 
calcium ATPase, a major contributor to metabolism (Infante, 1987).    
Eicosanoid Synthesis. Essential fatty acids incorporated into the plasma 
membrane are also used to produce cell-signaling molecules called eicosanoids. 
Eicosanoids such as leukotrienes, prostaglandins, and thromboxanes act as cell 
mediators to modulate numerous processes such as inflammation, immunity, and 
thrombogenesis. Both EPA and AA may be used to synthesize eicosanoids, but 
the specific type of eicosanoid produced varies depending on the availability of 
free EPA and AA (Harizi, Corcuff, & Gualde, 2008). Because n-6 FAs are usually 
present in higher quantities in cell membranes, eicosanoids derived from AA are 
typically formed more readily (Harizi et al., 2008). 
Unsaturated fatty acids used for eicosanoid synthesis come from the 
phospholipids of inflammatory cell membranes. Physiological stimuli (such as 
elevated epinephrine or antigen-antibody complexes), or pathological stimuli may 
act on a specific tissue to stimulate eicosanoid production. In response, 
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phospholipase A2 (PLA2) acts on cell membranes to liberate AA or EPA from the 
phospholipid bilayer (Gropper et al., 2009; A. Simopoulos, 2006). Specifically, 
PLA2 cleaves the ester bond linking the fatty acid to the second carbon on the 
glycerol backbone, releasing a fatty acid (Gropper et al., 2009).  
AA can be converted to the 2 series of prostaglandins and the 4 series of 
leukotrienes and thromboxanes, while EPA is the precursor to the 5 series of 
leukotrienes and the 3 series of prostaglandins (Calder, 2010; Das, 2005). EPA 
and DHA may also be converted to E-series and D-series resolvins, respectively, 
which are important in inflammation suppression (C. N. Serhan et al., 2002; 
Charles N Serhan, Gotlinger, Hong, & Arita, 2004).  
The pathways converting free EPA and AA to their respective eicosanoids 
utilize many of the same major enzymes, yet those generated from EPA have 
slightly different structures and presumably weaker effects than those from AA 
(Harizi et al., 2008). If present in large quantities, AA-derived eicosanoids 
generally promote an inflamed, prothrombotic physiologic state. Conversely, 
EPA-derived eicosanoids typically have either weakly pro-inflammatory or anti-
inflammatory properties. Thus, it is believed that high dietary consumption of n-6 
FA and low n-3 FA consumption can promote inflammatory conditions (Calder, 
2006).  
Arachidonic Acid-Derived Eicosanoids. Three different classes of enzymes 
may act on free AA to produce bioactive eicosanoids: cyclooxygenases (COXs), 
lipoxygenases (LOXs) or P-450 epoxygenases (Calder, 2006). COX exists in 
different isoenzymes as either COX-1 or COX-2. COX-1 is a constitutive enzyme, 
meaning it is not controlled by induction or repression and is present at all times. 
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Conversely, COX-2 is an inducible enzyme, so the level of its expression depends 
on physiological conditions (Calder, 2006). AA-derived eicosanoids include 
leukotriences, lipoxins, prostaglandins, thromboxanes, and hydroxy fatty acids 
(Harizi et al., 2008). The COX pathways produce prostaglandins PGD2, PGE2, 
and PGF2a, prostacyclin, and the thromboxanes TXA2 and TXB2 (A. Simopoulos, 
2006). PGE2, an AA-derived eicosanoid, has received special attention for its 
powerful abilities to increase inflammation, resulting in effects such as 
vasodilation, edema, pain, and fever (Stanke-Labesque et al., 2008). The LOX 
pathway is responsible for converting AA into various leukotrienes, 
hydroxyeicosatetraenoic acids (HETEs), and lipoxins. P-450 epoxygenases 
synthesize HETEs and epoxides (Calder, 2006). The AA-derived eicosanoids, such 
as PGE2, generally have strong inflammatory potential. However, some evidence 
has shown that the lipoxins may actually decrease inflammation (Das, 2005) and 
stop neutrophil migration and adhesion (Chiang, Arita, & Serhan, 2005). 
EPA and DHA-Derived Eicosanoids. Metabolism of EPA and DHA are 
affected by dietary n-3 FA intake, as n-3 FAs compete with n-6 FAs for both 
incorporation into cell membranes and interaction with COX and 5-LOX (Calder, 
2006). This effect has been demonstrated in humans; for instance, fish oil 
supplementation has been shown to cause an increase in the production of 
certain leukotrienes, such as LTB5 and LTE5, and a decrease in LTB4 and 
prostaglandin E2 (PGE2) (Teitelbaum & Allan Walker, 2001; Thies et al., 2001). 
In contrast with AA-derived eicosanoids, EPA-derived eicosanoids, such as LTB5, 
exert weak inflammatory or even anti-inflammatory effects (Stanke-Labesque et 
al., 2008; Teitelbaum & Allan Walker, 2001). Moreover, EPA-derived eicosanoids 
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may antagonize the actions of AA-derived eicosanoids, ultimately limiting their 
inflammatory potential (Calder, 2010). For instance, Tull, et al., demonstrated 
through an in vitro study that generation of EPA-derived eicosanoids inhibited 
the recruitment and migration of neutrophils (Tull et al., 2009). Expression of 
leukocyte adhesion molecules, which is typically stimulated by cytokines, was 
suppressed after DHA supplementation in endothelial cells. As a result, 
inflammatory markers, including IL-1 and IL-6, were significantly decreased in 
the cells that received DHA supplementation (DeCaterina, Liao, & Libby, 2000). 
Observations such as these have led to the belief that increased n-3 FA intake 
weakens the inflammatory response (Molendi-Coste et al., 2011).  
EPA and DHA may also be used in the COX-2 pathway to produce the E-
series and D-series resolvins, respectively. Resolvins are anti-inflammatory 
mediators that have been shown to block generation of inflammatory markers 
such as TNF-! and IL-6, ultimately decreasing leukocyte recruitment and pro-
inflammatory cytokine generation (Das, 2005). Low cellular concentrations of 
resolvins may increase adherence of macrophages to endothelial cells, leading to 
endothelial injury that is characteristic of chronic inflammatory diseases such as 
coronary artery disease (Das, 2005).    
 
Inflammation 
Acute & Chronic Inflammation. Inflammation is a natural and essential 
response to physical, chemical, or biological stressors, such as injury and 
infection (Stienstra et al., 2007). In acute inflammation, leukocytes, 
macrophages, and eicosanoids are recruited to destroy injurious stimuli (Calder, 
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2006). If successful, a process of tissue repair and inflammatory cell apoptosis 
follows, and homeostasis is reestablished (Jernås et al., 2006). If the harmful 
agent is not eliminated, however, chronic inflammation persists through systemic 
recruitment of macrophages and inflammatory mediators such as interleukins 6 
and 8 (IL-6 and IL-8), tumor necrosis factor-alpha (TNF-!), and C-reactive 
protein (CRP) (Monteiro & Azevedo, 2010), potentially damaging surrounding 
tissues (Wall et al., 2010).  
Anti-Inflammatory Effects of Omega-3 Fatty Acids. Omega-3 fatty acids 
have been found to attenuate the effects of some chronic inflammatory 
conditions, including rheumatoid arthritis and atherosclerosis (Monteiro & 
Azevedo, 2010). Several mechanisms have been proposed to explain the ability 
of n-3 FAs to decrease systemic inflammation both indirectly and directly.  
Because n-3 and n-6 FAs compete for assimilation into plasma 
membranes, n-3 FA intake decreases the concentration of AA in tissues (Calder, 
2006). This leaves less substrate available for production of AA-derived 
eicosanoids, thereby indirectly suppressing the inflammatory response (Calder, 
2010). Furthermore, by competing with AA for metabolism through the COX and 
LOX pathways, n-3 FAs are able to decrease production of AA-derived, pro-
inflammatory eicosanoids (Tull et al., 2009; Wall et al., 2010). Instead, higher 
levels of less-potent eicosanoids, and possibly even anti-inflammatory 
eicosanoids, are produced (Calder, 2010).  
In addition to antagonizing AA-derived eicosanoid inflammation, resolvins 
and lipoxins produced from EPA and DHA have the potential to decrease 
inflammation directly by blocking cytokines and decreasing neutrophil migration 
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(Charles N Serhan et al., 2004; Wall et al., 2010). The ultimate systemic results 
of these mechanisms are evidenced by suppressed leukocyte chemotaxis and 
decreased production of reactive oxygen species and adhesion molecules 
(Calder, 2010).  
Moreover, n-3 FAs may induce anti-inflammatory effects on a genetic 
level (Calder, 2009, 2010; Wall et al., 2010). PPARs are known to antagonize the 
effects of nuclear factor kappa B (NFkB), which is a transcription factor that 
regulates the production of adhesion molecules and pro-inflammatory mediators 
(including IL-6 and TNF-!). As ligands for PPARs, PUFAs (particularly n-3 FAs) 
are able to indirectly suppress NFkB activity (Wall et al., 2010). Furthermore, 
some evidence suggests EPA may inhibit NFkB activity by altering its activation. 
Under normal conditions, NFkB is activated through phosphorylation, yet cells 
cultured with n-3 FAs demonstrated less phosphorylation of NFkB as compared 
to cells cultured with n-6 FAs (Babcock et al., 2003). Thus, n-3 FAs seem to 
reduce the ability of kinases to activate NFkB (Calder, 2009).  
 
Current Literature Studying n-3 FA Intake and Body Composition 
Animal and In Vitro Studies. Although limited, some evidence suggests n-
3 FAs may decrease basal metabolic rates in rodents, which could lead to 
decreased body mass over time. Vegiopoulos, et al., studied the role of COX-2 
(an enzyme critical to eicosanoid synthesis) in BAT activity in mice. Investigators 
found that inhibition of COX-2 led to decreased BAT thermogenesis and a 
reduction in basal metabolic rate, ultimately leading to increased adiposity. 
Proinflammatory AA-derived eicosanoids are believed to increase mitochondrial 
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thermogenesis by up-regulating UCP1. This suggests that n-3 FAs, which 
compete with AA for metabolism by COX-2, may lead to a reduction in 
thermogenesis and a consequential increase in adiposity (Vegiopoulos et al., 
2010). 
Other studies suggest dietary n-3 FA decreases adiposity. An in vitro 
study by Kim, et al., demonstrated antiadipogenic effects of DHA. Preadipocytes 
exposed to DHA displayed decreased lipid accumulation. Furthermore, DHA led 
to increased adipocyte apoptosis. Investigators reasoned that DHA was 
incorporated into cellular plasma membranes (leading to decreased 
concentration of AA in membrane phospholipids), thus decreasing production of 
AA-derived eicosanoids, which are typically associated with cell proliferation. 
Lipolysis in mature, fully differentiated adipocytes, was also stimulated after 
introduction of DHA (Kim, Della-Fera, Lin, & Baile, 2006). Thus, n-3 FAs may 
encourage adipocyte apoptosis, discourage accretion of lipids in adipocytes, and 
increase lipolysis to make fewer lipids available for adipocyte uptake.   
Animal studies have found similar results. Ruzickova, et al., found that 
when a portion of a high fat diet was replaced with EPA and DHA, rodents 
accumulated less epididymal fat and displayed less weight gain when compared 
to rodents on a control high fat diet. Observed differences could not be explained 
by variances in caloric intake, suggesting EPA and DHA may have played a role in 
the rodents’ metabolism. Based on these results, however, it is predicted that 
humans consuming 100g of fat per day would need to replace 11g of dietary fat 
with EPA/DHA in order to see a decrease in obesity (Ruzickova et al., 2004). This 
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would be equivalent to approximately 5-7 servings of oily fish per day, which far 
exceeds the current dietary recommendations (Flock & Kris-Etherton, 2011).  
Belzung, et al., observed a dose-dependent decrease in epididymal and 
peritoneal adipose tissue accretion in rodents consuming EPA and DHA as part of 
a high-fat diet. Investigators suggested that EPA and DHA may play a role in 
limiting adipocyte hypertrophy (Belzung, Raclot, & Groscolas, 1993). In a study 
by Raclot, et al., not only did investigators find that dietary n-3 FA led to 
decreased adipocyte hypertrophy in rodents, but they also found that expression 
of metabolic enzymes, including fatty acid synthase and lipoprotein lipase, 
decreased in rodents receiving EPA and/or DHA (Raclot, Groscolas, Langin, & 
Ferré, 1997). This suggests that n-3 FAs may play a role in expression of 
enzymes needed for lipogenesis and lipid oxidation (Raclot et al., 1997).  
Omega-3 fatty acids may also have implications in appetite regulation. A 
2006 study showed that rats fed EPA had increased levels of leptin (an 
anorexigenic hormone) and decreased caloric intake (Pérez-Matute, Pérez-
Echarri, Martínez, Marti, & Moreno-Aliaga, 2007). Furthermore, a study by 
Takahashi and Ide also demonstrated decreased intake and a consequential 
reduction in adiposity in mice fed an EPA/DHA-enriched diet (Takahashi & Ide, 
2000).  
Human studies showing weight gain. Although the mechanism is elusive, 
several studies in humans have demonstrated that frequent consumers of fish 
tend to weigh more (Table 2). Iso, et al., distributed food frequency 
questionnaires to healthy female registered nurses between the ages of 34 and 
59 and followed nearly 80,000 of them for 14 years. Although the primary 
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objective of the study was to observe stroke risk as related to fish consumption, 
investigators noted that women who reportedly consumed over two servings of 
fish per week (approximately 0.5 g n-3 FA per day) were more likely to be 
overweight than non-fish eaters (Iso, 2001). Because the study was a 
prospective cohort study, however, no definitive conclusions could be drawn 
about the specific effects of fish consumption.   
Fish oil supplementation (>1.5g/day, or >5 servings of fish per week) has 
been shown to be effective in treatment of cancer cachexia, a condition 
characterized by hypermetabolism, inflammation, decreased appetite, and 
marked decreases in body weight (particularly lean body mass) secondary to 
certain forms of cancer (Colomer et al., 2007). EPA and DHA found in fish oil are 
believed to decrease levels of proinflammatory cytokines, possibly leading to 
greater lean body mass accretion, although no conclusive mechanistic 
explanations have been drawn (Colomer et al., 2007; Fearon et al., 2003; 
Grimble, 2003). Fearon, et al, randomized 200 men and women with 
unresectable pancreatic cancer to either a n-3 FA supplement group (consuming 
approximately 2.2 g EPA per day) or placebo group for eight weeks. Those in the 
experimental group demonstrated increased dietary intake as compared to 
control subjects during the intervention. A significant positive correlation was 
also observed between supplement intake and gains in total body weight (r = 
0.5, p < 0.001) and lean body mass (r = 0.33, p < 0.05) only in the 
experimental group (Fearon et al., 2003).  
Similarly, a double-blind, placebo-controlled trial by Irving, et al., studied 
the effects of fish oil supplementation (1.7 g DHA plus 0.6 g EPA per day) on 
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body weight and appetite in Alzheimer’s patients. Subjects receiving fish oil 
supplementation (n=89) had gained an average of 0.7 ± 2.5 kg 6 months into 
the study (p=0.02), whereas the placebo group (n=85) showed no significant 
weight change. Those in the intervention group also showed improved appetite 
after 12 months (p=0.01) based on caregivers’ ratings. Investigators also 
examined C-Reactive Protein (CRP) levels (an inflammatory marker), noting that 
weight gain increased as CRP levels decreased, indicating inflammation and 
appetite and/or weight gain may be correlated in Alzheimer’s disease patients. 
These effects were seen despite the fact that Alzheimer’s patients typically lose 
weight as the disease progresses (Irving et al., 2009).  
A similar trend was observed in a study that looked at the impact of 
dietary PUFAs on cardiovascular disease risk markers. The 24-week study 
randomly assigned overweight men and women to either the control group or 
one of four intervention groups varying by type of fish consumed (either oily fish 
supplying approximately 4.5 g EPA + DHA per week, or white fish supplying 
approximately 0.7 g EPA + DHA per week), and types of visible fats used (high in 
sunflower oil providing LA, or high in rapeseed oil, which is low in LA) for the 
duration of the study. Subjects in the oily fish/sunflower intervention group 
unexpectedly showed weight gain, while those in the white fish/sunflower group 
demonstrated weight loss, despite the fact that no significant differences in 
calorie intake were observed (Moore et al., 2006). Because the effects of n-3 FAs 
on weight were not the primary objectives of this study, however, it is difficult to 
determine whether observations resulted because of the addition of dietary fish 
oils, or because of confounding variables, such as physical activity.  
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The above studies observed the effects of fish oil on older subjects or 
subjects with chronic disease and/or inflammation. However, Damsgaard, et al., 
provided fish oil supplements to 66 young (19-40 years old), healthy men in a 
randomized, double-blind study for 8 weeks. Investigators measured 
cardiovascular disease risk markers, including body weight. Investigators showed 
that subjects receiving fish oil (1.8 g EPA + 1.1 g DHA per day provided in 
capsules) and consuming visible fats high in linoleic acid gained an average of 
0.7 kg over the course of the study (p<0.05). However, this trend was not seen 
in any other subjects, including those receiving fish oil supplements and 
consuming visible fats low in linoleic acid (Damsgaard, Frøkiaer, Andersen, & 
Lauritzen, 2008).  
Human Studies Showing Weight Loss. Some intervention studies also 
suggest a relationship between n-3 FAs and decreased body weight (Table 2). 
In a cross-sectional study, Micallef, et al., measured plasma n-3 FAs of 124 adult 
men and women (aged 18-70, healthy, overweight, and obese). Higher plasma 
n-3 FA levels were associated with healthier anthropometric measurements (BMI, 
waist circumference, and hip circumference), and obese subjects had 
significantly lower plasma n-3 FA levels when compared to healthy-weight 
individuals (Micallef et al., 2009). Although no definitive conclusions may be 
drawn from this study, the results suggest plasma n-3 FA levels may be inversely 
related to BMI.  
Hill et al. observed the effects of fish oil supplementation paired with 
exercise on body composition and cardiovascular health in adults at risk for 
cardiovascular disease. 75 subjects with a BMI >25 kg/m2 and hypertension, 
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elevated cholesterol, or high triacylglycerol levels were randomized to one of 
three intervention groups: fish oil supplementation alone (supplying ~1.9 g n-3 
FA per day), fish oil supplementation plus exercise, sunflower oil 
supplementation alone (control), or sunflower oil plus exercise. Over the course 
of the 12 week study, percent body fat was reduced only in the exercise groups, 
but those in the fish oil plus exercise group lost approximately 1.5 kg fat, which 
is significantly more than those in the sunflower oil plus exercise group (Hill et 
al., 2007). 
Kunesova, et al., studied the effects of n-3 FA supplementation (2.8 g 
EPA + DHA per day) and a very low calorie diet on fat oxidation in obese 
women. After the 21-day intervention, women in the placebo group lost 
significantly less weight than those receiving the fish oil, and showed lower levels 
of beta-oxidation as measured by serum beta-hydroxybutyrate levels. There was 
also an inverse relationship between phospholipid DHA change and BMI change 
(r= -0.595, p<0.008). Investigators concluded that the efficacy of a very low 
calorie diet might be enhanced when paired with fish oil supplementation. 
However, the sample size was relatively small, (n=20), and the study was 
performed in an inpatient setting, making it difficult to generalize results to a 
broader population (Kunesová et al., 2006). 
In a high-constraint crossover study by Couet, et al., 6 g/day of visible 
dietary fats were replaced by fish oils for three weeks, and consequential 
changes in metabolic rate, substrate oxidation, and body composition as 
measured by dual-energy X-ray absorptiometry (DXA) were studied. Subjects 
were young and healthy (aged 23 ± 2y; BMI 21.9 ± 1.6 kg/m2 ). All meals were 
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prepared and measured by a dietitian to ensure that caloric intake was 
accurately recorded. Although no significant difference in weight loss was 
observed, investigators observed an increase in resting metabolic rate, increase 
in fat oxidation, and a decrease in body fat mass (-0.88 ± 0.16 kg, p<0.05) 
during the fish oil intervention. Although significant, it is difficult to generalize 
these results to a broad population since it was such a high-constraint study. 
Furthermore, the sample size was relatively small (n=6), and only one subject 
was female, making it difficult to draw conclusions about the effects of n-3 FA 
supplementation on female body composition (Couet et al., 1997).  
Human Interventions Showing No Effect or Mixed Results. Not all studies 
have found a significant relationship between fish oil supplementation and 
alterations in body weight or body composition (Table 2). For instance, a 10-
week parallel-arm study randomized 32 healthy, sedentary adult males to one of 
four groups: control (usual diet and physical activity), fish oil supplementation 
(approximately 4g n-3 FA per day), exercise, or fish plus exercise group. No 
significant change in body fat percentage was found in any of the intervention 
groups (Brilla & Landerholm, 1990).   
Similarly, DeFina, et al randomized sedentary obese or overweight males 
and females (aged 30-60 years) to take either a fish oil intervention group 
(receiving 12.5 g EPA + 2.5 g DHA divided into 5 capsules per day) or placebo 
control group (1:1 ratio of soybean and corn oil in 5 capsules per day) in a 
double-blind parallel arm trial. Subjects in both groups received lifestyle 
counseling to promote weight reduction. Although subjects in both groups lost 
weight, there were no statistically significant differences in weight reduction 
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between the two groups as indicated by body weight, BMI, body fat percentage, 
or waist circumference. There were also no significant differences in resting 
metabolic rate between the two groups (Defina et al., 2011).  
Thorsdottir, et al, placed 324 overweight men and women on a weight 
loss diet and randomly assigned them to consume either 3 servings/week oily 
fish (supplying 2.1 g/d EPA + DHA), 3 servings/week lean white fish (supplying 
0.26 g/d EPA + DHA) 6 capsules of fish oil/day (supplying 1.3 g/d EPA + DHA), 
or 6 placebo oil capsules/day and no seafood. All of the men consuming seafood 
(either lean or oily fish) or taking fish oil capsules lost an average of 1 kg more 
weight than those in the placebo group. No significant differences were seen in 
women, however. The authors theorized that this gender difference could be 
related to a difference in reaction to marine foods in men an women. One 
possibility for this is that women have an enhance ability to convert ALA to DHA 
as compared to men, so supplementation of n-3 FAs may not have had as 
profound of an effect on women (Thorsdottir et al., 2007).  
Krebs, et al., compared a weight loss intervention paired with a fish oil 
supplement (1.3 g EPA + 2.9 g DHA per day) to the same intervention with a 
placebo oil supplement (2.8 g LA + 1.4 g oleic acid per day) in overweight, 
hyperinsulinemic women. Despite seeing decreased inflammatory markers and 
lipid profiles in fish oil subjects, no significant difference in weight loss was 
observed between the two groups, suggesting fish oil is effective in treatment of 
chronic inflammation and clinical manifestations associated with obesity (such as 
hyperlipidemia), but not necessarily in weight loss itself (Krebs et al., 2006). 
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Others still have only found fish oil supplementation to be effective in 
weight loss promotion only when paired with a weight loss regimen. For 
instance, Warner, et al., conducted a randomized controlled parallel-arm study 
and assigned 34 hyperlipidemic subjects to either a corn oil supplement, fish oil 
supplement, fish oil plus exercise, or control (no exercise or supplement) group. 
Over the course of the 12-week study, a significant reduction in body fat was 
observed only in those taking fish oil and exercising. However, the amount of 
fish oil supplemented per day was extremely high (14g EPA and 10g DHA/day), 
potentially introducing the risk of prolonged bleeding times, and making it 
difficult to determine whether lower levels of supplementation would be effective 
in reducing body fat (Warner et al., 1989).  
Table 2. Available Literature. Studies in humans observing the 
relationship between omega-3 fatty acids and changes in body weight and/or 
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or no weight 
loss program 
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+ 1.4 g oleic 
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Subjects & Study Design. Healthy, non-obese women at Arizona State 
University between the ages of 18 and 38 were recruited through email using 
Arizona State University ListServs. Interested subjects were referred to an online 
survey (Appendix B) to determine eligibility based on diet, physical activity, 
smoking habits, brief medical history, and self-reported BMI. Eligible subjects 
were contacted to schedule a screening visit (study visit 1).   
During the screening visit, subjects completed a written consent 
(Appendix C). Next, subjects completed a brief medical history questionnaire 
(Appendix D) and validated omega-3 fatty acid food frequency questionnaire 
(FFQ) (Appendix E). Anthropometric measurements, including weight, height, 
and percent body fat, were also be measured. Height and weight were measured 
using a stadiometer and calibrated scale. BMI and percent body fat were 
determined using a bioelectrical impedance scale (Tanita).  
Exclusion criteria included regular smoking (use of >10 cigarettes per 
day), BMI >30 or BMI <18.5, regular use of omega-3 or fish oil supplements, 
vegetarian dietary patterns (excluding all fish, meat, and poultry from the diet), 
regular consumption of one or more 3.5oz servings of fish per week, and/or use 
of prescription medications that may interfere with body weight or inflammatory 
state (such as corticosteroids or non-steroidal anti-inflammatory drugs). Potential 
subjects taking birth control were excluded if they had been taking the drug for 
less than three months. Women who were pregnant or lactating, as well as 
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competing and/or training athletes were excluded. Furthermore, subjects with 
any unresolved health issues were not used in the study. Finally, anyone who 
has had the seasonal flu shot was excluded because of the accompanying study.   
To determine a sample size, a power analysis was performed using a 
probability of 0.05 and a power of 0.8, along with a verified sample size 
calculator (Schoenfeld, 2010). Based on prior human interventions testing the 
effect of a dietary supplement on body weight, an expected change of 1.9 kg 
and a standard deviation of 1.3 were used. This calculation suggested that a 
total of 18 subjects would be adequate for a randomized, parallel arm trial 
(Appendix F). A total of 35 subjects were enrolled in the study, which allowed for 
18 subjects in the fish oil group (FISH) and 17 subjects in the coconut oil placebo 
group (CON). However, 9 total subjects were lost to attrition throughout the 
study, leaving 13 subjects in each group (for a total of 26 subjects) that 
completed the study.  
Qualifying subjects entering the 8-week trial were stratified based on age, 
BMI, weight, and n-3 FA consumption as indicated by the omega-3 FFQ, and 
randomly assigned to either the experimental (fish oil, FISH) or control (placebo, 
CON) group. Random assignments to groups were performed by a coin toss.  
During the baseline study visit (study visit 2), a 24-hour recall was 
performed to understand typical dietary patterns and estimate caloric intake. 
Next, supplements were administered using a double-blind procedure to prevent 
bias during data collection and analysis. Subjects received either placebo 
(Puritan’s Pride brand, coconut oil softgels, 1000mg each) or fish oil capsules 
(EnergyFirst brand, USP-certified fish oil softgels, 400mg EPA + 200mg 
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DHA/capsule), which were similarly-sized gel capsules. Subjects were instructed 
to ingest one capsule in the morning, preferably with food, and check off each 
day that capsule was taken on provided calendar (Appendix G). Subjects also 
received booklets containing validated Godin Leisure-Time Exercise 
questionnaires to complete weekly (Appendix H) and validated daily cold 
symptom surveys for accompanying study (Appendix I) during visit 2. Subjects 
were asked to document alcohol, cigarettes, medications, and supplements used 
each day at the bottom of each cold symptom survey. An explanation of all 
questionnaires was provided during subject meetings, and a practice-run was 
completed before subjects left study visit 2. Height, weight, BMI, and percent 
body fat measurements were taken during the baseline visit (using a stadiometer 
and bioelectrical impedance scale, Tanita) and a fasting blood sample was 
collected for the accompanying study.  
Visits at weeks 4 and 8 began with body weight, percent body fat, and 
BMI measurements. Unused capsules from the previous weeks were returned 
during these visits using a double-blind procedure, and remaining study materials 
(booklets containing physical activity log and capsules for weeks 5-8) were 
distributed during the week 4 visit. A final 24-hour dietary recall and fasting 
blood sample were also performed during the final visit for the accompanying 
study (week 8). 
Compliance to capsule administration was monitored through capsule 
counts at weeks 4 and 8. Biweekly emails from a blind master list were also sent 
to all subjects to check for compliance to study protocol.  
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Statistical Analysis. SPSS Version 19.0 was used to perform statistical 
analysis, and Food Processor SQL was used to assess 24-hour recalls. Weekly 
leisure time exercise was measured in MET-hours per week, which was 
determined by multiplying the numbers of reported mild, moderate, and 
strenuous physical activity sessions by 3, 5, or 9, respectively. Unless indicated 
otherwise, data is reported as means ± standard error (SE). Differences in 
means of outcome variables were compared using 2-tailed independent t-tests, 
univariate analysis of variance, or repeated measures analysis of variance. Data 
were tested for normality, and non-parametric tests were used for data that 
were not normally distributed. Differences in variables were considered 
significant at p"0.05.  
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Chapter 4 
DATA & RESULTS 
Recruitment for this double blind, placebo-controlled, parallel-arm trial 
took place in January and February 2012. A total of 163 people completed the 
Internet survey, but only 53 were contacted for a screening visit due to exclusion 
criteria. A total of 43 females attended the initial screening visit. Of the 43 
participants screened, 35 were enrolled in the study. Participants were then 
stratified by age, body weight, BMI, and n-3 FA intake (as measured by a FFQ 
administered during the screening visit), and randomly assigned to the 
intervention (FISH) or control (CON) group. This resulted in 18 subjects in the 
FISH group and 17 subjects in the CON group. However, 8 participants dropped 
out of the study before the week 1 visit due to apparent lack of interest, 
scheduling conflicts, or loss of communication, and one participant dropped out 
after the week 4 visit due to loss of communication. Thus, 13 subjects in the 
CON group and 13 subjects in the FISH group completed the study and were 
used for data analysis. There was an overall 93.3% compliance rate in the FISH 
group and a 92.3% compliance rate in the CON group based on the number of 
capsules leftover at the mid-point (4 weeks) and end (8 weeks) of the 
intervention. Although average compliance decreased in the FISH group between 
the first and second half of the study, compliance remained above 91% for both 
groups throughout the course of the study (Table 3, Figure 1).  
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Table 3. Compliance. Average percentage of capsules taken based on 
number of capsules returned 1,2 
  Weeks 1-4 Weeks 5-8 Weeks 1-8 
FISH 94.8 ± 0.02 % 91.6 ± 0.03% 93.3 ± 0.02% 
CON 92.6 ± 0.02% 91.8 ± 0.03% 92.3 ± 0.03% 
ALL 93.7 ± 0.02% 91.7 ± 0.02% 92.8 ± 0.02% 
1FISH - fish oil group, 400mg/d EPA + 200mg/d DHA; CON - placebo 
group, 1000mg/d coconut oil; ALL – All subjects 
2Values reported as means ± SE  
 
Figure 1. Compliance to capsule administration as measured by average 
percentage of capsules taken. 
 
 
Independent t-tests showed that subjects in the FISH and CON groups 
were similar upon enrollment in the study (Table 4). The mean age of each 
group was similar (24.0 ± 1.6 years for FISH and 23.0 ± 1.7 years for CON) and 
ranged from 18-38 years in both groups. Baseline body weight, BMI, and percent 
body fat recorded at the screening visit did not differ significantly between 
groups. Omega-3 fatty acid intake as indicated by the FFQ completed at the 
screening visit (study visit 1) was also similar between the two groups. The 
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g/d in the CON group (p=0.137). 24-hour recalls performed at the second study 
visit (Day 0 for the 8-week intervention) showed that baseline caloric and EFA 
intake was also similar between the two groups (1664 ± 117 kcal/day for FISH 
and 1742 ± 137 kcal/day for CON, p=0.669).  
Table 4. Baseline Characteristics of Participants1,2 
 All (n=26) FISH (n=13) CON (n=13) P-value 
Age (y) 23.5 ± 1.1 24.0 ± 1.6 23.0 ± 1.7 0.3393 
Weight (lb) 144.1 ± 4.4 140.7 ± 6.1 147.6 ± 6.5 0.4244 
BMI (kg/m2) 23.7 ± 0.6 23.2 ± 0.8 24.2 ± 0.9 0.4244 
Body Fat Percent 29.2 ± 1.3 28.4 ± 2.0 30.1 ± 1.8 0.5204 
Daily n-3 FA 
intake FFQ (g) 
0.6 ± 0.08 0.7  ± 0.1 0.4  ± 0.07 0.1373 
Linolenic Acid 
(g/d) 24h recall5 0.5 ± 0.1 0.5 ± 0.1 0.6 ± 0.2 0.573
3 
Linoleic Acid (g/d)  





1703 ± 89 1664 ± 117 1742 ± 137 0.6694 
1FISH - fish oil group, 400mg/d EPA + 200mg/d DHA; CON - placebo 
group, 1000mg/d coconut oil; ALL – All subjects 
2Values reported as means ± SE  
3Data not normally distributed; analysis by Mann Whitney test 
4Data normally distributed; analysis by independent t-test 
5Data collected immediatley prior to the start of the intervention (study 
visit 2)  
 
Changes in body weight, BMI, and percent body fat between week 8 and 
week 1 of the intervention were not strongly correlated with potential 
confounding variables, including baseline n-3 FA intake, consumption of non-
steroidal anti-inflammatory drugs (NSAIDS), prescription medications, alcoholic 
or caffeinated beverages, and exercise per week (Table 5). Baseline energy 
intake as determined by 24-hour recalls at the start of week 1 correlated 
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significantly with both body weight and BMI (p=0.048 and p=0.031, 
respectively). However, the strength of these relationships was only moderately 
positive (r=0.391 for energy intake and body weight, and r=0.425 for energy 
intake and BMI), so they were not controlled for during data analysis.  
Table 5. Potential Confounding Variables. Correlations between potential 








coefficient (r) P-Value 
Age (years) 
Weight difference -0.390 0.850 -0.129 0.531 
BMI difference -0.053 0.797 -0.148 0.472 
Body fat 
percentage 
difference 0.081 0.695 0.099 0.630 
Weight (lbs) at week 1  
Weight difference 0.086 0.675 -0.056 0.787 
BMI difference 0.089 0.666 -0.017 0.935 
Body fat 
percentage 
difference -0.009 0.966 -0.020 0.923 
Linolenic Acid Intake (g/d) at baseline (FFQ) 
Weight difference -0.214 0.293 -0.290 0.151 
BMI difference -0.244 0.230 -0.335 0.094 
Body fat 
percentage 
difference -0.033 0.873 -0.086 0.675 
Baseline Energy Intake (kcal/day, based on week 1 24-hour recall)  
Weight difference 0.391 0.048* 0.325 0.105 
BMI difference 0.425 0.031* 0.393 0.047* 
Body fat 
percentage 
difference 0.298 0.139 0.222 0.276 
Change in Energy Intake (week 8 kcal – week 1 kcal, based on 24-hour recalls 
Weight difference 0.201 0.358 0.271 0.211 
BMI difference 0.132 0.549 0.190 0.385 
Body fat 
percentage 
difference 0.149 0.497 0.180 0.412 
Capsule Compliance (% of total capsules taken) 
Weight difference 0.040 0.846 0.125 0.544 
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BMI difference 0.039 0.174 0.136 0.509 
Body fat 
percentage 
difference 0.174 0.394 0.043 0.834 
NSAIDS taken (total days consumed during study) 
Weight difference 0.077 0.708 0.069 0.736 
BMI difference 0.068 0.742 0.068 0.741 
Body fat 
percentage 
difference 0.023 0.911 0.076 0.711 
Other prescription (total days consumed during study) 
Weight difference -0.006 0.976 -0.074 0.718 
BMI difference 0.027 0.897 -0.017 0.936 
Body fat 
percentage 
difference 0.039 0.849 -0.054 0.794 
Alcohol (total days consumed during study) 
Weight difference 0.020 0.921 -0.103 0.616 
BMI difference -0.023 0.912 -0.135 0.510 
Body fat 
percentage 
difference 0.194 0.343 0.251 0.216 
Caffeine (Ave. # beverages per day) 
Weight difference 0.176 0.391 0.089 0.664 
BMI difference -0.041 0.844 0.126 0.540 
Body fat 
percentage 
difference 0.177 0.386 0.071 0.730 
Strenuous exercise (Ave. # days/wk) 
Weight difference 0.091 0.657 0.070 0.733 
BMI difference 0.056 0.784 0.013 0.949 
Body fat 
percentage 
difference 0.057 0.782 0.183 0.372 
Moderate exercise (Ave. # days/wk) 
Weight difference -0.103 0.616 -0.211 0.300 
BMI difference -0.128 0.533 -0.185 0.366 
Body fat 
percentage    
difference -0.035 0.867 0.018 0.930 
Mild exercise (Ave. # days/wk) 
Weight difference -0.062 0.765 -0.082 0.691 
BMI difference -0.071 0.730 -0.054 0.794 
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Body fat 
percentage 
difference 0.052 0.801 0.033 0.873 
Overall physical activity (METS-hours/wk)  
Weight difference 0.097 0.693 -0.006 0.981 
BMI difference 0.111 0.652 0.004 0.989 
Body fat 
percentage 
difference 0.101 0.681 0.183 0.453 
*Statistically significant at the 0.05 level 
 
After 4 weeks of the intervention, univariate analysis did not demonstrate 
significant differences in body weight or composition measurements between the 
FISH and CON groups (Table 6). Subjects in the FISH group had gained an 
average of 0.68 ± 0.61 lbs, while the CON group had lost an average of 0.49 ± 
0.59 lbs (p=0.180). Despite the weight loss demonstrated in the CON group, 
body fat percent increased by 0.015 ± 0.24% in the CON group and by 0.29 ± 
0.50% in the FISH group. However, this change was not statistically significant 
(p=0.621).  
Table 6. Mean Body Composition Differences Weeks 1-4 (difference = wk 4 - 
wk 0) 1,2 





0.092 ± 0.43 0.68 ± 0.61 -0.49 ± 0.59 0.180 0.074 
BMI (kg/m2) 0.012 ± 0.073 0.092 ± 0.11 -0.069 ± 0.097 0.280 0.048 
Body Fat 
Percent (%) 
0.15 ± 0.27 0.29 ± 0.50 0.015 ± 0.24 0.621 0.010 
1FISH - fish oil group, 400mg/d EPA + 200mg/d DHA; CON - placebo group, 
1000mg/d coconut oil; ALL – all subjects 
2Values reported as means ± SE  
3P-value and effect size represent univariate analysis; all data are normally 
distributed; controlling for baseline energy intake did not alter results 
 
 Upon completion of the 8-week intervention, subjects in the FISH group 
had gained an average of 0.29 ± 0.45 lbs, while those in the CON group had 
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gained an average of 0.092 ± 0.67 lbs (Figure2, Figure 3). The difference in 
the change in weight between the two groups was not statistically significant 
(p=0.830). Both groups experienced nearly the same overall increase in BMI 
(0.023 ± 0.11 kg/m2 in the FISH group and 0.023 ± 0.12 kg/m2 in the CON 
group, p=1.00) (Figure 2, Figure 4). Body fat percentage also increased in 
both groups (0.48 ± 0.46% in FISH and 0.22 ± 0.18 in CON), but the difference 
in the change in body fat percentage between the two groups was not 
statistically significant (p=0.600) (Figure 2, Figure 5, and Table 7). Because 
daily caloric intake has a direct effect on body weight and composition, analysis 
of the change in body weight, BMI, and body fat percentage was reassessed 
using multivariate analysis while controlling for the difference in energy intake 
between the beginning (week 1) and end (week 8) of the intervention. However, 
there were still no significant differences in body weight or composition changes 
between the FISH and CON groups (p=0.664 for change in body weight, 
p=0.545 for BMI, and p=0.508 for body fat percent).  
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Table 7. Mean Body Composition Differences Weeks 1-8 (difference = wk 8 - 
wk 1) 1,2 





































0.600 0.012 0.508 0.022 
1FISH - fish oil group, 400mg/d EPA + 200mg/d DHA; CON - placebo group, 
1000mg/d coconut oil; ALL – all subjects 
2Values reported as means ± SE 
3P-value and effect size represent univariate analysis; all data are normally 
distributed; controlling for baseline energy intake did not alter results 
4P-value and effect size represent multivariate analysis with the change in energy 
intake (week 8 kcal/d – week 1 kcal/d) as covariate 
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Figure 2. Changes in main outcome measures throughout the course of the 




Figure 3. Change in body weight for FISH and CON groups at the beginning, 
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Figure 4. Change in body mass index for FISH and CON groups at the 
beginning, middle, and end of the study.  
 
 
Figure 5. Change in percent body fat for FISH and CON groups at the 




 24-hour dietary recalls were performed at weeks 1 and 8 and analyzed 
using Food Processor SQL (“Food Processor SQL,” n.d.) in order to control for 
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throughout the study (Table 8). The FISH group reported an 11% increased 
mean energy intake at week 8 as compared to week 1, while the mean caloric 
intake of the CON group decreased by approximately 13% over the course of the 
study (Figure 6). A boxplot displaying the differences in caloric intake between 
weeks 1 and 8 of the intervention is shown below (Figure 7). Although the 
changes in caloric intake differed between the FISH and CON groups, this trend 
did not achieve statistical significance when analyzed using repeated measures 
multivariate analysis of variance (p=0.069). These differences were analyzed 
again using week 1 body weight as a covariate, which caused the trend to 
further approach statistical significance (p=0.055). There were no statistically 
significant differences in linolenic or linoleic acid intake between the FISH and 
CON groups or within each group at weeks 1 and 8. Linolenic acid intake was 
also assessed using a validated FFQ, but no statistically significant differences 
between FISH and CON groups throughout the course of the study were 
observed.  
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Table 8. Dietary Data at Weeks 0, 1, and 81,2 
 











Total energy intake (kcal), 24 hour recall 
FISH ND 1664 ± 117 1853 ± 161 
CON ND 1742 ± 137 1520 ± 123 
ALL ND 1703 ± 89 1687 ± 105 
0.0694 0.131 N/A 
Linolenic acid intake (g/d), 24 hour recall 
FISH5 ND 0.48 ± 0.1 0.62 ± 0.2 
CON5 ND 0.53 ± 0.2 0.48 ±0.1 
ALL ND 0.50 ± 0.1 0.55 ± 0.1 
N/A 0.058 0.975 
Linoleic acid intake (g/d), 24 hour recall 
FISH ND 4.7 ± 1.2 5.09 ± 1.3 
CON5 ND 4.9 ± 1.4 4.53 ± 1.1 
ALL ND 5.2 ± 0.9 4.81 ± 0.8 
N/A 0.004 0.778 












ND 0.60 ± 0.1 
N/A 0.017 0.174 
1FISH -  fish oil group (n=13), 400mg/d EPA + 200mg/d DHA; CON - placebo group 
(n=13), 1000mg/d coconut oil; ALL – all subjects (n=26); ND – No data; N/A – Not 
applicable 
2Values reported as means ± SE; values do not include additional 0.6 g/d fat 
provided by fish oil supplement for FISH subjects  
3Effect size determined using repeated measures multivariate analysis of variance  
4P=0.055 when controlling for body weight (lbs) at week 1  
5Data are not normally distributed 
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Figure 6. Comparison of mean energy intake for FISH and CON groups as 




Figure 7. Boxplot displaying the change in energy intake for subjects in the 
FISH and CON groups as determined by 24-hour recalls performed at the 















Mean Energy Intake at Weeks 1 and 8 
P=0.069  
Week 1 
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 In this double blind, randomized, placebo-controlled trial, 8 weeks of n-3 
FA supplementation (600 mg EPA + DHA per day) did not change body weight, 
BMI, or body fat percentage in young healthy women as compared to a placebo 
(1000 mg coconut oil per day). These findings do not refute the current 
recommendations for Americans to consume at least 8 oz of fish per week, 
supplying 250 mg EPA and DHA per day (Flock & Kris-Etherton, 2011).  
Although not statistically significant, 24-hour dietary recalls performed at 
the beginning and end of the intervention revealed a trend towards increased 
daily caloric intake in the FISH group and decreased daily energy intake in the 
CON group throughout the course of the study (p=0.069). This trend approached 
significance when week 1 body weight was controlled for (p=0.055). If 
maintained, this difference in caloric intake (an average of approximately 150-
200 kcal/d) could lead to changes in body weight over time.  
Interestingly, other research has looked into the potential for n-3 FAs to 
alter caloric intake. Previous studies in our lab showed that subjects consuming 
fish as the sole source of flesh food weighed more and had higher caloric intake 
as compared to those consuming a vegetarian or regular diet. Some studies have 
observed a link between n-3 FA intake and levels of appetite-regulating 
hormones. For instance, leptin is an anorexigenic adipokine, and its synthesis is 
positively correlated with adipocyte size. Thus, leptin helps to achieve energy 
homeostasis by decreasing appetite when excess adipose tissue is present (Cave 
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et al., 2008). Drevon, et al demonstrated a decrease in leptin production after 
providing rats with high levels of n-3 FA. Investigators also observed an increase 
in lipid oxidation in rats fed high levels of n-3 FAs, and speculated that increased 
lipid oxidation may have led to reduced leptin concentration (Drevon, 2005). In 
an in vitro study, cells cultured with DHA and EPA demonstrated decreased leptin 
mRNA expression. This decrease would theoretically lead to a decline in satiety 
and increase in energy intake (Drevon, 2005). However, the levels of n-3 FAs 
provided by these studies are not physiologically relevant for humans, as they 
would require intake much higher than current recommendations.  
Research has also observed a potential link between EPA and DHA intake 
and ghrelin levels. Ghrelin is an appetite-stimulating hormone produced in the 
stomach, and appears to occur in lower levels in obese as compared to lean 
populations. Various factors are believed to influence ghrelin expression, 
including dietary fat intake. Some evidence suggests low dietary fat intake during 
periods of fasting leads to decreased ghrelin expression, which translates to a 
decline in appetite (Ramel, Parra, Martinéz, Kiely, & Thorsdottir, 2009). Thus, it 
is interesting to think that increased fat intake may lead to increased ghrelin 
production. In an 8-week randomized, placebo-controlled, parallel-arm trial, 324 
overweight adult men and women were placed on calorie-restricted diets with 
either no seafood (control, 0 g/d n-3 FAs), three servings of lean white fish per 
week (providing 0.26 g/d n-3 FAs), three servings of oily fish per week (providing 
2.1 g/d n-3 FAs), or daily fish oil capsules (providing 1.3 g/d n-3 FAs). Although 
all groups lost weight, only women in the fish oil supplementation group 
demonstrated higher ghrelin levels at the end of the intervention. This effect was 
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not seen in men (Ramel et al., 2009). Moreover, significant differences in weight 
loss as a result of EPA and DHA consumption were observed only males in the 
study, while no difference in weight loss was observed in females (Thorsdottir et 
al., 2007). Although not clear from this study, it is possible that the increased 
ghrelin observed in the women taking fish oil may have been the reason no 
significant differences in weight loss were observed. Although the increased 
ghrelin levels observed in women could have been related to calorie restriction 
and weight loss during the intervention, it is interesting to note that these effects 
were not observed in men, who experienced even more weight loss. Moreover, 
there were no statistically significant differences in weight loss between women 
in the 4 intervention groups, so it would not be logical that their ghrelin levels 
would be significantly different.  
More research is needed to identify the potential for n-3 FAs to modulate 
appetite-regulating hormones. The present study protocol only used two 24-hour 
recalls to characterize caloric intake, so it is difficult to accurately depict trends in 
energy intake, hunger, and satiety throughout the study. Because there is no 
gold standard for dietary analysis, it is difficult to draw definitive conclusions 
about appetite and caloric intake from dietary recalls alone. Furthermore, the 
validity and reliability of 24-hour recalls is limited by the memory of the 
participant and the ability of the participant to estimate portion sizes. 24-hour 
recalls also assume that the previous day accurately characterizes typical caloric 
and nutrient intake, which may lead to flawed generalizations (Thompson, Subar, 
Loria, Reedy, & Baranowski, 2010).  
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Mean caloric intake for the CON group also decreased by nearly 200 
kcal/d throughout the course of the study. This was not anticipated, as coconut 
oil does not supply EFAs and consists primarily of medium chain triglycerides and 
saturated fatty acids. Thus, 1 g of fat from coconut oil should be a trivial 
amount, and should not be an effective dose. Moreover, typical daily fat intake 
for females aged 20-39 years is approximately 67g (US Department of Health 
and Human Services, 2012).    
Interestingly, several studies have observed decreased caloric intake as a 
result of coconut oil supplementation. For instance, Assunção, et al., found that 
coconut oil may decrease carbohydrate intake by increasing insulin secretion. 
However, these effects were observed only when 30mL (approximately 28g) of 
dietary fats were replaced with coconut oil (Assunção, Ferreira, dos Santos, 
Cabral, & Florêncio, 2009). The present study provided about 3.5% of the dose 
provided by Assunção and colleagues. In a 12-week intervention, Han, et al., 
randomly assigned 40 type 2 diabetic Chinese adults to replace a portion of their 
dietary fats with either medium chain triglycerides (MCT) from coconut oil (18 
g/d) or long chain triglycerides (LCT). MCT consumption was linked to decreased 
total caloric intake and body weight in men and women (Han et al., 2007). Once 
again, however, this dose was considerably higher than the one provided by the 
present study protocol.  
In order to obtain more accurate results in future studies, blood 
concentrations of the appetite-modulating hormones leptin and ghrelin could be 
tracked. The use of several methods of dietary assessment, such as food 
records, or more frequent 24 hour recalls, would provide a more accurate 
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perception of caloric intake as related to fish oil supplementation. Participants 
could also be given questionnaires to identify perceived changes in satiety, 
hunger, or food cravings to estimate the effects of these changes in hormone 
levels, if any.  
 The direction of weight and BMI change for both the FISH and CON 
groups changed at week 4 (Figures 3, 4, and 5). It is not clear why these 
changes were observed, as average capsule compliance remained above 90% in 
both groups for both the first and second halves of the study (Table 3). It is 
possible that the metabolic response to n-3 FA supplementation changed as 
plasma levels of n-3 FAs increased and leveled off. Arterburn, et al., showed that 
plasma DHA concentrations equilibrated after 4 weeks of supplementation, which 
is the same amount of time subjects in this study had been supplementing with 
n-3 FAs before the change in trend direction was observed. However, this 
saturation point occurred in the Arterburn study after 1.2 g/d n-3 FA 
supplementation, which is twice the amount of n-3 FAs provided by this study’s 
protocol (Arterburn et al., 2006). 
 Another possibility is that dietary n-3 or n-6 FA intake changed at week 4, 
leading to a consequential change in LA-derived eicosanoid production 
(depending on the ratio of n-6 to n-3 FAs in cellular plasma membranes) at the 
mid-point of this study. Changes in dietary intake could have off-set the effects 
of the supplement, potentially modulating appetite, thermogenesis, or lipid 
homeostasis, and leading to the difference in weight changes observed between 
the first and second halves of the study. However, this study design only 
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collected information on n-3 and n-6 FA intake at the beginning and end of the 
study, so it is difficult to determine if changes occurred at the mid-point.  
 In future studies, it would be beneficial to track plasma EPA, DHA, and 
AA levels at multiple points throughout the study to ensure plasma n-3 FA levels 
are stable. This could also reveal potential changes in outcome measures once 
saturation is reached in cell plasma membranes.  
It is important to note that subjects in this study were young (23.5 ± 1.1 
years) women with a healthy BMI (23.7 ± 0.6 kg/m2) and no prior health 
conditions. It is therefore difficult to generalize these results to other 
populations, such as those with some level of chronic inflammation, older 
subjects, or overweight and obese populations. It is also not possible to 
generalize these results to male populations. This is particularly true since 
women tend to metabolize ALA (a source of n-3 FAs) more efficiently than men, 
meaning young males may respond differently to the same level of n-3 FA 
supplementation (Arterburn et al., 2006). 
There are a number of reasons why significantly different changes in 
body weight may not have been observed between FISH and CON groups. 
Because the women used in this trial were healthy and non-obese (BMI = 23.7 ± 
0.6 kg/m2), baseline inflammation might not have been extreme enough to be 
manipulated by n-3 FA supplementation. A majority of studies observing 
significant results studied obese or chronically inflamed populations (Hill et al., 
2007; Krebs et al., 2006; Kunesová et al., 2006; Moore et al., 2006; Warner et 
al., 1989). Thus, there may have been a more pronounced effect of n-3 FAs on 
suppressing inflammation in these previous studies.  
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Moreover, it is possible that n-3 FA supplementation may have had 
multiple contradictory effects on metabolism and appetite, leading to no 
significant changes overall. Previous studies have hypothesized a number of 
mechanisms by which n-3 FAs may modulate weight and body composition in a 
positive or negative direction. These mechanisms include increased lipid 
oxidation, upregulation of UCP1 to increase thermogenesis, decreased resting 
metabolic rate due to inflammation suppression, or increased appetite due to 
increased ghrelin production and decreased leptin production. It is unclear under 
which conditions and to what degree these metabolic changes occur, so it is 
possible that multiple changes could have led to an insignificant net weight 
change.  
It is also possible that the n-3 FA supplements altered body composition 
but not overall body weight. This was seen in the Couet, et al. study, which 
observed no significant change in body weight but a decrease in body fat 
accretion when subjects ingested n-3 FAs (Couet et al., 1997). Percent body fat 
was measured in the present study at weeks 1, 4, and 8 using bioelectrical 
impedance analysis (BIA), and revealed no significant changes between weeks 1 
and 8. BIA is a relatively inexpensive, convenient, and noninvasive method for 
measuring body fatness, but the precision and validity of these results can be 
limited by individual variations in body shape and hydration status (Kyle et al., 
2004). Dual energy X-ray absortiometry (DXA), which was used in the Couet, et 
al. study, is generally revered as the gold standard for body composition 
measurement. However, this method is costly and requires trained personnel. A 
combination of multiple measures of body composition, such as skin fold tests, 
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waist circumference measurements, and BIA might have been more effective in 
detecting body composition changes.  
Finally, the amount of n-3 FA provided in this study (600 g/d) was 
relatively low. Other studies have demonstrated significant changes in body 
weight after supplementation of more than 2-3 g/d fish oils (Couet et al., 1997; 
Kunesová et al., 2006) and studies in rodents have used even higher doses 
(Flachs et al., 2006). It is possible that a subtherapeutic dose, such as the one 
provided in this study, may be ineffective in altering body weight. However, 
therapeutic doses seem impractical, as they exceed recommendations from the 
American Heart Association and USDA. They also likely require administration of 
multiple pills each day, or consumption of several servings of oily fish per day. 
For some consumers, this could be unrealistic. Furthermore, therapeutic doses of 
fish oils could lead to unwanted side-effects such as prolonged bleeding time 
(Iso, 2001) or gastrointestinal symptoms (National Center for Complementary 
and Alternative Medicine, 2009).  
Limitations. This trial has several limitations. The 8-week intervention was 
relatively short compared to other studies, especially since weight can fluctuate 
substantially due to factors such as hydration. The study protocol also did not 
include testing participants’ baseline EFA levels. If the women already had 
adequate n-3 FA and cells were at saturation, it is possible that supplementation 
may not have had any profound effects. Additionally, the potential metabolic 
changes that could incur with decreased inflammation may result in subtle 
changes in energy balance or adiposity that would not be evident in just a few 
weeks. A longer intervention may make these subtle changes more apparent.  
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Despite the goal to enroll 40 females in the trial, only 26 completed the study 
due to scheduling and recruitment restrictions, which may have made it difficult 
to observe significant changes.  
Strengths. Participants were screened for a number of exclusion criteria 
prior to enrollment in the study. These criteria included frequent fish 
consumption, regular smoking, BMI of less than 18.5 or more than 30, and 
regular intake of omega-3 supplements and/or prescription medications that 
could have interfered with body weight or inflammatory state (such as 
corticosteroids or non-steroidal anti-inflammatory drugs). These exclusion criteria 
helped to ensure subjects were relatively similar upon enrollment in the study, 
and minimized the potential for prior conditions or lifestyles to interfere with the 
study protocol. Since physical activity was monitored weekly with the Godin 
Leisure-Time Exercise questionnaire, change in physical activity was eliminated 
as a potential confounding variable. Furthermore, the double-blind nature of this 
trial minimized bias by preventing investigators and participants from knowing 
what treatment they were receiving. 
Conclusion. This randomized controlled trial suggests that daily 
supplementation of n-3 FA (600 mg/d EPA + DHA) for 8 weeks does not lead to 
changes in body weight, BMI, or percent body fat in young healthy women as 
compared to placebo. These results do not refute the recommendation for 
Americans to increase weekly seafood consumption to approximately 8 oz fish 
per week. However, further research is needed to investigate the effects of n-3 
FAs on appetite, as well as the effects of prolonged supplementation on body 
weight and body composition.  
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Nutrient Supplementation and Health Parameters 
 
INTRODUCTION 
The purposes of this form are to provide you (as a prospective research study 
participant) information that may affect your decision as to whether or not to participate 




Dr. Carol Johnston, Director of the Nutrition Program at Arizona State University, as well 
as Nutrition graduate students, Megan Gutierrez and Bianca Teran, have invited your 
participation in a research study. 
 
STUDY PURPOSE 
The purpose of the research is to examine the effect of nutrient supplementation in 
young college females, 18-40 years old, on immune function and overall health. 
 
DESCRIPTION OF RESEARCH STUDY 
If you decide to participate, then as a study participant you will join a study to evaluate 
the effect of ingestion of a supplement daily for 8 weeks on health markers. You will be 
instructed to complete a one-page questionnaire daily regarding illness. If you are 
interested in joining the study, you will be asked to come to an initial screening where 
your height and weight will be measured and you will complete a health history and diet 
quality questionnaires. If you are eligible for the study, you and the other participants will 
be randomly assigned in either the control (placebo) or experimental (nutrient 
supplement) group. Subjects will be asked to visit the research site on 3 occasions at 0, 
4, and 8 weeks. At weeks 0, 4, and 8 you will be weighed. At weeks 0 and 8 a fasting 
blood sample will be drawn. At each blood sampling approximately 4 tablespoons of 
blood will be collected.  At weeks 4 and 8 you will complete a diet quality questionnaire 
and you will need to bring in your daily survey booklet with your supplement pack.  
 
If you say YES, then your participation will last for 8 weeks at the Downtown Phoenix 
campus at Arizona State University. Approximately 40 subjects will be participating in 
this study locally. 
 
RISKS 
There may be a slight chance of gastrointestinal distress when taking the supplement on 
an empty stomach. This risk is reduced if you ingest the supplement with a meal and 
consume plenty of water. Blood draws may cause light-headedness or temporary 
bruising. A nurse or trained phlebotomist will be performing the blood draws. 
 
BENEFITS  
Although there may be no direct benefits to you, the possible benefit of your participation 
is that you will be able to experience what it is like to be a part of a research study that 




If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you. 
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is required 
by law. The results of this research study may be used in reports, presentations, and 
publications, but the researchers will not identify you. Your name will not be associated 
with any data related to the study. In order to maintain confidentiality of your records, 
you will be assigned to a subject 
number by Dr. Carol Johnston, which will be used throughout the course of the study to 
identify you. Only Dr. Johnston will have access to subject names and their 
corresponding codes.  
 
WITHDRAWAL PRIVILEGE 
It is ok for you to say no. Even if you say yes now, you are free to say no later, and 
withdraw from the study at any time. Your decision will not affect your relationship with 
Arizona State University or otherwise cause a loss of benefits to which you might 
otherwise be entitled.  
 
COSTS AND PAYMENTS 
The researchers want your decision about participating in the study to be absolutely 
voluntary, yet they recognize that your participation may pose some costs such as 
inconvenience and a small time commitment. In order to help defray your costs, you will 
receive a $10 Target gift card at week 4 and a $15 Target gift card at week 8 visits for a 
total of $25. 
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your 




Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Dr. Carol Johnston, Principal 
Investigator and Professor of Nutrition at ASU (480-727-1713), Megan Gutierrez, 
Graduate Student (440-452-5142), or Bianca Teran, Graduate Student (520-370-2441). 
 
If you have questions about your rights as a subject/participant in this research, or if you 
feel you have been placed at risk; you can contact the Chair of the Human Subjects 
Institutional Review Board, through the ASU Office of Research Integrity and Assurance, 
at 480-965 6788.   
 
This form explains the nature, demands, benefits and any risk of the project.  By signing 
this form you agree knowingly to assume any risks involved.  Remember, your 
participation is voluntary.  You may choose not to participate or to withdraw your consent 
and discontinue participation at any time without penalty or loss of benefit.  In signing 
this consent form, you are not waiving any legal claims, rights, or remedies.  A copy of 
this consent form will be given (offered) to you.   
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Your signature below indicates that you consent to participate in the above study.   
 
___________________________ _________________________ _____ 
Subject's Signature   Printed Name    Date 
 





"I certify that I have explained to the above individual the nature and purpose, the 
potential benefits and possible risks associated with participation in this research study, 
have answered any questions that have been raised, and have witnessed the above 
signature. These elements of Informed Consent conform to the Assurance given by 
Arizona State University to the Office for Human Research Protections to protect the 
rights of human subjects. I have provided (offered) the subject/participant a copy of this 
signed consent document." 
 




































































































































































Basu, et al.  Parallel 35 0.7 2.5 6 
Thom, E Parallel  40 2.0 3.5 14 
Couet, et al.  Crossover 6 0.62 0.7 28 
Blankson, et al. Parallel 60 2.0 0.8 200 









































Godin Leisure-Time Exercise Questionnaire 
 
 
1. During a typical 7-Day period (a week), how many times on the average 
do you do the following kinds of exercise for more than 15 minutes during 
your free time (write on each line the appropriate number). 
 
 
      Times Per 
       Week: 
 
a) STRENUOUS EXERCISE  
(HEART BEATS RAPIDLY)             __________ 
(e.g., running, jogging, hockey, football, soccer, 
squash, basketball, cross country skiing, judo, 
roller skating, vigorous swimming, 
vigorous long distance bicycling) 
 
 
b) MODERATE EXERCISE 
(NOT EXHAUSTING)             __________ 
(e.g., fast walking, baseball, tennis, easy bicycling, 
volleyball, badminton, easy swimming, alpine skiing, 
popular and folk dancing) 
 
 
c) MILD EXERCISE 
(MINIMAL EFFORT)              __________ 
(e.g., yoga, archery, fishing from river bank, bowling, 





2. During a typical 7-Day period (a week), in your leisure time, how often 
do you engage in any regular activity long enough to work up a sweat 
(heart beats rapidly)? 
 
             OFTEN   SOMETIMES  NEVER/RARELY 
 








































































• Sent to Arizona State University ListServs 
• Inclusion based upon: 
• Gender (women) 
• Age (18-40 years old) 
• Non-obese 
• Invitation to Complete Internet Survey 
Initial Contact: Email   
• Exclusion based upon:  
• Smoking Habits (>10 cigarettes/day) 
• Vigorous physical activity (> 5 times/week) 
• Regular fish consumption (>1 serving/week) 
• Fish oil supplementation 
• Seafood Allergies 
• Seasonal flu shot 
• Pregnant or lactating 
Internet Survey 
• Informed Consent 
• Medical History Questionnaire 
• Omega-3 Food Frequency Questionnaire 
• Height & Weight 
• Percent Body Fat and BMI (Tanita) 
Study Visit 1: Screening 
• Weight & Percent Body Fat (Tanita) 
• 24-hr Recall 
• Fasting Blood Sample 
• Survey Booklet Distribution and Explanation 
• Capsule Distribution and Explanation 
Study Visit 2: Baseline 
• Weight & Percent Body Fat (Tanita) 
• Collect Remaining Capsules 
• Collect Booklets (Weeks 0-4) 
• Distribute Weeks 5-8 Material (Surveys and 
Capsules) 
• Distribute $10 Gift Cards 
Study Visit 3: Week 4 
• Weight & Percent Body Fat (Tanita)  
• 24-hr Recall 
• Omega-3 Food Frequency Questionnaire 
• Fasting Blood Sample  
• Collect Remaining Capsules 
• Collect Booklets (Weeks 5-8) 
• Distribute $15 Gift Cards 
Study Visit 4: Week 8 
